INDEX

Indexer: Dr Laurence Errington
www.errington-index.demon.co.uk

Figures and tables are comprehensively referred to from the text. Therefore, significant material in figures and tables has only been given a page reference in the absence of their concomitant mention in the text referring to that figure.

Abbreviations: AI (or FI), anal (faecal) incontinence; EMG, electromyography; LUT, lower urinary tract; LUTS, lower urinary tract symptoms; POP, pelvic organ prolapse; QoL, quality of life; SUI, stress urinary incontinence; UI, urinary incontinence. UK and not US spellings have been used throughout the index, although the text uses both.

A

Aδ fibres/axons, 176, 636
abdominal approach see transabdominal approach
abdominal examination, females with UI, 342
abdominal leak point pressure, 419
abdominal massage aiding defaecation, 868-9
spinal cord injury, 907
abdominoperineal resection of rectum, 802, 918
absorbent products (pads) for FI, 1530, 1556
odour control, 1627
absorbent products (pads) for UI, 1538-57
capacity and user requirements, 1544
categories, 1538-40
changing frequency, 1623, 1625
evaluation of different bodyworn designs, 1550-4
females with light UI, 1527, 1544-6
general recommendations on selection, 1556-7
for light UI
females, 1527
males, 1528, 1546-8
materials, 1540-4
measuring usage, 336
for moderate/heavy UI
females, 1528
males, 1529
ACET study, 647
acetaminophen, chronic pelvic pain, 1490
acetohydroxamic acid, 1597
acetylcholine, 128, 131, 175, 639-41
detrusor overactivity and, 263, 639-41
urothelial stretch and, 118
see also muscarinic receptors; nicotinic receptors
acetylcholinesterase inhibitors see cholinesterase inhibitors
Acticon Neosphincter®, 1396, 1398
actin in detrusor contraction, 121
activities of daily living and frailty, 964
acupuncture
male UI, 1093
nocturnal enuresis, 724
adenosine receptors, 131-2
adenosine triphosphate see ATP
ADH see vasopressin
adherence (compliance)
children, 1741-2
electrical stimulation, 1067
pelvic floor muscle training, 1044-5, 1045-6, 1047, 1651
adhesives, tissue, non-obstetric fistulas, 1249
adjunct radiotherapy in prostate cancer, 1139
adrenoceptor(s) (and adrenergic nerves/innervation), 129
adverse urinary effects in older people of drugs acting at, 310, 311
bladder wall/detrusor, 123
as novel molecular targets, 140
α-adrenoceptor, 126, 129
bladder, 126, 129, 202
urethral, 127
urethral and anal rhodosphincters and, 194
α-adrenoceptor agonists/stimulants, SUI, vs pelvic floor muscle training, 1051
α-adrenoceptor antagonists, 657
multiple system atrophy, 884-5
neurogenic UI, 824-5
children, 743
older people, adverse urinary effects, 311
overactive bladder symptoms/detrusor overactivity, 657
overactive pelvic floor, children, 739
overflow incontinence, 676
β-adrenoceptor, 140-1
β3-adrenoceptor, 123, 658
agonists, 140, 141
overactive bladder symptoms/detrusor overactivity, 657-8
SUI, 673-4
antagonists, SUI, 673
bladder, 129
as novel molecular targets, 140-1
urethral, 127
advanced glycation end-products, 134
advanced practice nurses, 1655
collaboration with physicians in care of frail elderly, 1004
advocacy, continence, 1652-8
aesthetics, pads, 1557
aetiology (incl. risk factors/pathogenesis), 1667-8
AI/FI, 74-9, 137, 286, 354, 861-3, 877-922, 1323-41, 1364-7
children, 764
frail elderly, 1362, 1364-7
neurogenic, 861-3, 877-922, 1338-9, 1365-6
obstetric factors see childbirth
physical examination in determination of cause, 354-5
bladder dysfunction see bladder dysfunction
bladder pain syndrome, 222, 1469-71
constipation, older people, 1356
enuresis/wetting
day, 45-6
night, 41-2
fistulas see fistulas
POP see pelvic organ prolapse
UI (in general), 1667-8
frail elderly, 965-75, 1009, 1739-40
men see males
neurological, 69, 799-802, 877-922
in primary prevention, 1667-8
research recommendations, 93
women, 55-61, 83
see also pathophysiology
afferents see sensory (afferent) nerves/neurones
African-American women see black and African-American women aganglionosis, colonic (Hirschsprung’s disease), 138
age (and aging)
AI/FI risk and, 74, 1330
bowel, 1363-4
of child, effects of incontinence and its treatment related, 1741
LUT changes with, 965-70
nocturnal enuresis prevalence and, 39-40, 41
non-neurogenic detrusor overactivity and, 260-1
outcome of female UI treatment related to bladder training, 1078
electrical stimulation, 1066-7
pelvic floor muscle training, 1054-5
outcome of male UI treatment related to, bladder training, 1092-3
pharmacology and, 981-3
POP and, 283
surgical management of, 1275
anticholinergics see antimuscarinics
anticonvulsants, chronic pelvic pain, 1491
antidepressants, 660
bladder pain syndrome, 1482-3
chronic pelvic pain, 1491
diarrhoea-associated FI, 1351
neurogenic UI, 821-2
nocturnal enuresis, 723
overactive bladder symptoms/detrusor overactivity, 660
SUI, 674-5
antidiarrhoeal drugs, 1350-1
antidiuretic hormone (ADH) see vasopressin
antiproliferative factor and bladder pain syndrome, 1470, 1478
antipseudics (anticonvulsants), chronic pelvic pain, 1491
anti-incontinence devices see continence devices
anti-kinking/twisting features
anti-incontinence appliances
urethral sphincter
for continent urinary diversion, 856
for antegrade continence enema, 1407
anti-incontinence devices see continence devices
水利尿素
anti-incontinence devices see continence devices
antiperistaltic effect and bladder pain syndrome, 1470, 1478
antipyretics, in chronic pelvic pain, 1490
anti-twisting features see anti-kinking features
anus
anatomy and function, 285-6
benign conditions associated with FI, 354
endovascular cushions, 286
fissure, chronic, 486
imperforate see imperforate anus
stimulation with water streams see water
see also anorectum; perianal examination and entries under anal; transanal
APCAB (Asia Pacific Continence Advisory Board), 1658
apnoea, sleep see sleep apnoea
apomorphine, 887
aponeurotic bladder neck slings, neurogenic LUT dysfunction, 846-7
apoptosis, detrusor smooth muscle cells, 148
appendix
for antegrade continence enema, 1407
for continent urinary diversion, 856
appliances see continence devices
aprepitant, 671-2
AQoL (Assessment of Quality of Life), 1696
Arabian medicine, 21
areflexia
detrusor see underactive bladder/detrusor
urethral sphincter see underactive urethral sphincter
L-arginine, bladder pain syndrome, 1485
Argus sling, 1130-1, 1137
arousal (from sleep), children
infants, 704
nocturnal enuresis and, 42, 717-18
alarm facilitating arousal see enuresis alarm
aural training, 724, 770
see also waking
artificial anal sphincter, 1396-8, 1408
neurogenic FI, 875-7
artificial bladder (prosthetic bladder), child, 750
artificial bowel sphincter, 1398
artificial urethral/urinary sphincter (=AUS), 845, 847-9, 1160-8
availability and cost, 1160
children, 751, 754
complications see safety
component durability, 1164-5
historical accounts, 29-30
men, 29-30, 1134-5, 1160-8
consensus protocol on follow-up, 1168
diagnostic evaluation of UI after placement, 1165-7
indications, 1161
post-prostatectomy (for benign disease), 453, 1134-5
post-prostatectomy (for cancer), 453, 1134-5
post-radiotherapy, 1139
technique, 1161-3
women, 29-30, 1255
ascending pathways/tracts, bladder control, 207
ASCRS (American Society of Colon and Rectal Surgeons) FQoL scale, 1402
ASERNIP-S (Australian Safety and Efficacy Register of New Interventonal Procedures - Surgical), 1754
Asia Pacific Continence Advisory Board (APCAB), 1658
Asian and Asian-American women, epidemiology
ASCRS (American Society of Colon and Rectal Surgeons) FIQL scale, 1402
 Associazione Italiana Donne Medico, 1681
Association National de Ostomizados e Incontinentes (Spain), 1682
Association for Continence Advice (ACA), 1682
Association Nationale de Ostomises e Incontinentes (Spain), 1682
Associazione Italiana Donne Medico, 1681
ASTRA (anterior transsphincteric transanal surgical approach) to rectourethral fistula repair (ASTRA), 1158
astrocytes, spinal cord, 183
ATP, 118, 123
K+ channel gating by, 122
purinoceptors and, 123, 130, 174, 178-9
and non-neurogenic detrusor overactivity, 262-3
as urethelial stretch-released factor, 118
atrial natriuretic hormone and nocturia in the frail elderly, 999
atrophy, urethral, with artificial urinary sphincter, 1163-4, 1167-8
atropine (hyoscyamine), overactive bladder symptoms/detrusor overactivity, 643, 822
australasia, obstetric, in developing world, 1429-35, 1453
frail elderly, 975-7, 1005-7, 1009
nocturia, 1000
of outcome see outcome
UI children see subheading above
frail elderly see subheadings above
initial, 333-53
patient-reported outcome, 364-7, 377-403
post-fistula repair, 1448-9
preoperative, men, 1124-6, 1169
see also diagnostic tests; history-taking; investigations; physical examination
Assessment of Quality of Life, 1696
Association for Continence Advice (ACA), 1682
Association National de Ostomises e Incontinentes (Spain), 1682
Associazione Italiana Donne Medico, 1681
ASTRA (anterior transsphincteric transanal surgical approach) to rectourethral fistula repair (ASTRA), 1158
astrocytes, spinal cord, 183
ATP, 118, 123
K+ channel gating by, 122
purinoceptors and, 123, 130, 174, 178-9
and non-neurogenic detrusor overactivity, 262-3
as urethelial stretch-released factor, 118
atrial natriuretic hormone and nocturia in the frail elderly, 999
atrophy, urethral, with artificial urinary sphincter, 1163-4, 1167-8
atropine (hyoscyamine), overactive bladder symptoms/detrusor overactivity, 643, 822
intravesical, 822-3
attention and modulation of brain responses to visceral stimuli, 232
attention deficit hyperactivity disorder (ADHD)
daytime wetting and, 763-4
nocturnal enuresis and, 762-3
augmentation cystoplasty see cystoplasty
Australia
continence awareness/promotion/services, 1648-9, 1650-1, 1680
continence nurse advisors, 1654
professional education, 1660
referral centres, 1655
Continence Foundation of, 1655
family doctor education in, 1660
Australian Safety and Efficacy Register of New Interventional Procedures - Surgical, 1754
Austria, continence organisation, 1680
authorship, guidelines for, 1757-8, 1758
auto-augmentation (bladder/detrusor myectomy or myotomy), 1149
child, 749
detrusor overactivity, 1240
men, 1149
neurogenic LUT dysfunction, 854
autografts, for suburethral sling, 1216
auto-augmentation (bladder/detrusor myectomy or myotomy), 1149
automatic bladder see reflex bladder
autonomic nervous system, 797
bladder, 198-200, 200-2
in bladder pain syndrome aetiology, 1470-1
dysfunction and neuropathy
in diabetes mellitus, 1339
in Guillain-Barre syndrome, 911
leading to FI, 289, 1339
tests (in generalised neuropathy), 537
functional testing, 536-7
hyperreflexia/dysreflexia
with catheters, 1607
with digital rectal stimulation, 868
with sacral anterior root stimulation, 840
see also enteric nervous system; ganglia; parasympathetic nervous system
autonomous hypothesis of spontaneous detrusor activity, 125
autoplasty, vesical, 1446-7
average volume voided, measurement, 336
Avicenna, 21
axon(s) (nerve fibres)
C- see C-fibres/axons
terminal, bladder, 200
azathioprine, bladder pain syndrome, 1484

Bacille Calmette-Guerin instillation in bladder pain syndrome, 1487
baclofen, detrusor overactivity, 668-70
bacterial infections, urothelium in, 117, 171
see also antibiotics
bacteriuria, 337
asymptomatic, 338
children with neurogenic detrusor-sphincter dysfunction, 743-4
frail elderly, 468, 469, 970
indwelling catheters and, 1590, 1592, 1593
non-continent urinary diversion and, 859
spinal cord injury, 902
bags
interanal (stool bag), 1614, 1617, 1618
urine drainage see drainage bags
balloon systems/devices
anal pressure measurement, 475
external urethral sphincter dilatation, 837
of indwelling catheters
cuffing on deflation, 1600-1
filling solution, 1589
inflation failure, 1605
inflation leading to water loss from balloon over time, 1589
size, 1590
intravaginal, for resistance treatment, 1044
passive compression of urethra in men, 1131-3
rectum
compliance estimates, 494-6
distension, 488-9
expulsion test, 500
retention test, 493
sensitivity measurement, 488
see also double balloon urethrogramy
barrier function, urethelium, 170
barrier products, 1623, 1624
barrier products, 1623, 1624
Barrington’s nucleus, 209, 228
basal ganglia lesions, 800
Parkinson’s disease, 887
baseline clinical and demographic data, ICS Standardization Committee recommendations, 1730
baseline techniques in cognitive-behavioural therapy, 769
BBUS-Q (Birmingham Bowel and Urinary Symptoms Questionnaire), 394
BCG, intravesical/intramural, in bladder pain syndrome, 1487
BCSQ (Bladder Control Self-Assessment Questionnaire), 385
BE-DRI (Behavior Enhances Drug Reduction of Incontinence), 1752
bed sores (pressure ulcers), 1620-1
bedpans see underpads
bedpans, 1526, 1535-7
bedwetting see nocturnal enuresis
Behavior Enhances Drug Reduction of Incontinence (BE-DRI), 1752
behaviour
health and treatment-seeking see help-seeking behaviour
homeostatic emotions driving, 226-7
behavioural disturbances, 760-7
FI and, 764-6
subclinical, 766-7
behavioural therapies and modifications, 813-15
bladder pain syndrome, 1480
FI in children, 1349
frail elderly, 984-8
nocturia, 1000
recommendations, 1008
neurogenic UI, 812, 813-15
trials/research, 1748-9
Belgium, continence organisation, 1680
beneficence, 1756
Benefit, Satisfaction and Willingness Questionnaire (BSW), 383, 384
benign prostatic hyperplasia/enlargement/obstruction - BPH/BPE/BPO (and benign prostatic disease in general), 302-3, 969-70
age-related occurrence, 969-70, 983-4
drug therapy of frail elderly, 1001
nocturia, 264-5
prostatectomy for see prostatectomy
PSA levels in, 352
questionnaires, 379, 381, 396-7, 401
UI, 302-3
beta-adrenoceptors see adrenoceptors
bethanechol
supersensitivity test, 807-8
therapeutic use
in detrusor areflexia, 825
frail elderly, 995
BFLUTS (Bristol female LUTS questionnaire), 377, 378
bias in trials, 1722
bilharziasis (schistosomiasis), contracted bladder, 746, 1151
bimanual examination in bladder pain syndrome, 1475
biofeedback (BF)
children, 770
day/night-time enuresis, 735
neurogenic detrusor-sphincter dysfunction, 743
FI, 1353-9, 1375-6
meningomyelocoele, 915
men (post-prostatectomy), pelvic floor muscle training plus,
1085, 1085-7
with electrical stimulation, 1090
women/vaginal, pelvic floor muscle training plus
alone, 1045, 1046-7, 1047, 1065
with electrical stimulation, 1065-6
biofilms, indwelling catheters, 1590-2
prevention, 1596-7
biomarkers, bladder pain syndrome, 1478
biomaterials for bladder augmentation, 854
biomechanical properties see mechanics
Bioplastique® see polydimethylsiloxane
biopsies, bladder pain syndrome, 1477
Birmingham Bowel and Urinary Symptoms Questionnaire (BBUS-Q), 394
birth see childbirth
BISF-W (Brief Index of Sexual Function for Women), 398
black and African-American women, epidemiology
POF, 83-4
UI, 53
bladder
afferent neurones see sensory nerves
agenesis, surgery, 745
in aging see older people
artificial see artificial bladder
augmentation see auto-augmentation; cystoplasty
automatic/reflex see reflex bladder
bladder/urinary tract see bladder dysfunction
denervating agents injected through/below
botulinum toxin injection, 662
sensations, assessment in cystometry, 534
in spinal cord injury, 900-1
sensations, assessment in cystometry, 534
objective, 420
stones see stones
support/suspension, imaging (of normal and defective support), 552-3
surgery circumventing see urinary diversion
reflex bladder see reflex bladder
sensations, 429
categorisation, 335
children (with enuresis), 712
in diabetes mellitus, 916-17
in spinal cord injury, 900-1
sensations, assessment in cystometry, 534
objective, 420
bladder pressure and relationship to, measurement see filling cystometry
pad test and, 619
residual see residual urine
weight, ultrasound, 563-4
see also entries under cyst-; intravesical; vesico-
Bladder and Bowel Health Foundation (UK), 1682
Bladder and Bowel Health website (Australia), 1649
bladder cancer
neobladder for, 1141
patient-reported outcome questionnaires, 401
risk
with enterocystoplasty, 853
with indwelling catheter use, 818, 1599-600
with multiple sclerosis, 895-6
with non-continent urinary diversion, 859
bladder capacity, 429
children, 704-5
maximum cystometric, 712
males, reduced, 1151, 1161
surgery, 1151, 1161
normal values, 429
bladder chart see frequency/volume chart
Bladder Control Self-Assessment Questionnaire (BCSQ), 385
bladder cooling reflex see ice water/ test
bladder diary see frequency/volume diary
bladder dysfunction (abnormal function and functional changes)
aetiology and pathogenesis, 636
neural mechanisms, 222-5, 636
with artificial urinary sphincter, 1163
treatment, 1167
neurological patients with, non-continent urinary diversion, 858
POP comorbid with, 284-5
post-prostatectomy, 306-7
bladder expression, 813-14
in spinal injury, 812
bladder flaps for urethral reconstruction (with fistulas), 1446
bladder neck (urethrovesical junction; bladder outlet)
endoscopic evaluation
female, 607-8
male, 609
interactions with other pelvic organs at efferent neural level, 203-5
mobility (and hypermobility), assessment, 342-3
needle suspension, 1202-3
obstruction see bladder outlet obstruction
open, causes and imaging, 601-2
support devices/prosthesis, intravaginal, 1572-5
surgery (incl. reconstruction), 1141-2
ultrasoundography, 561-2
see also detrusor-sphincter dyssynergia
bladder neck (urethrovesical junction; bladder outlet) surgery (incl. reconstruction)
children, 750-5
neck closure, 752
reconstructive, 752-3
with extrophy/epispadias, 1143-4, 1161
repeat/revision, 1145
neurogenic LUT dysfunction, 845-7
complete closure, 845-6
in traumatic injuries, 1141-2
bladder outlet see bladder neck; bladder outlet obstruction
bladder outlet obstruction (outflow obstruction; BOO), 259-60
children, assessment, 712
endopelvic fascia
stress
in damage caused by, 148
men
PSA levels and, 352-3
research, 1736
urodynamic studies, 450
pathophysiology, 259-60
neural mechanisms, 222-5, 259-60, 260
women, postoperative, 1234
bladder pain syndrome (BPS; interstitial cystitis), 222, 1459-518
aetiology/pathogenesis, 222, 1469-71
classification, 1480
subgrouping/phenotyping patients, 1474, 1502
clinical symptom scales, 1494-8
co-morbid disorders, 225
definition/nomenclature/taxonomy, 1461-2, 1464-6, 1503, 1745
diagnosis, 1474-9, 1502
differential, 1479
epidemiology, 1446-9, 1502
outcome, assessment, 1498-501
pathology, 1473-4
report, 1478
research, 1502-3, 1745-6
treatment, 1480-8, 1492-4, 1501, 1503
conservative, 1480-1, 1501
drug, 1481-8
refractoriness, recommended management, 1502, 1503
surgical, 1492-4
bladder reflex see micturition reflex
bladder rehabilitation (urotherapy), children, 734-6, 769-71
bladder relaxants (incl. smooth muscle relaxants), 820, 821-2
mixed antimuscarinic and, 653
in neurogenic UI, 821-2
spinal cord injury, 903
see also specific (classes of) drugs
bladder retraining see bladder training
Bladder Self-Assessment Questionnaire (B-SAQ), 385
bladder-sphincter dysfunction see bladder dysfunction; urethral sphincter dysfunction
bladder training (BT; bladder retraining/discipline/drill/re-education), 815
children, 734
men, 1092-2
women, 1053, 1077-1, 1071-7, 1077-8
future research directions, 1082
other treatments combined with, 1053, 1076
other treatments vs, 1049, 1050, 1051, 1074-5
protocols, 1072-3
recommendations for practice, 1080-1
bladder wall
anatomy, 116
biomechanical properties, 132-7
smooth muscle see detrusor thickness, ultrasonography, 562-4
bleeding/haemorrhage, SUI surgery, 1233-4
blinding in trials, 1716, 1722
mistakes, 1719
block randomisation, 1720-1
blood, urinary (haematuria), 337
blood test, 626
preoperative, men, 1124
blood vessels, SUI surgery-related damage, 1233-4
blowing off, sheaths, prevention, 1558
BNDF (brain-derived neurotrophic factor), 181-2
body mass and UI risk, 1667
women, 57
bodyworn continence devices, 1544-54
absorbent products (pads), 1538-40
women, 1546-8
men, 1527, 1546-8
children, 664, 739, 743
in bladder pain syndrome, 1488
bladder emptying facilitated by, 825
in bladder pain syndrome, 1488
children, 664, 739, 743
in detrusor overactivity, 662-8, 1146
economic analysis, 666, 1699
in GI tract spasticity, 1148
in outcomes research, 1731
questionnaires, 377, 387, 388-9
ICI modular questionnaire, 371
Botulinum toxin A see botulinum toxin A
botulinum toxin A (Botox® and Dysport® ), 661-6, 823-4, 1146, 1148
bladder emptying facilitated by, 825
in bladder pain syndrome, 1488
children, 664, 739, 743
in detrusor overactivity, 662-8, 1146
economic analysis, 666, 1699
in GI tract spasticity, 1148
in outcomes research, 1731
questionnaires, 377, 387, 388-9
ICI modular questionnaire, 371
Botulinum toxin B (Neurobloc® ), 666
bowl (intestine/lower GI tract), 137-40
afferent projections to spinal cord, 182-4
ageing, 1363-4
bladder reconstruction/augmentation using (=enterocystoplasty), 849-53, 1160, 1239-40
alternatives to, 853-5
in bladder pain syndrome, 1493-4
children, 458, 747-50
complications, 755-9
in detrusor overactivity, 1239-40
in exstrophy-epispadia complex, 1144
indications, 849
neuropathic patients, 458
non-obstetric fistulas, 1251
results, 850-1
technical aspects, 849-53
bladder replacement using see neobladder
brain interactions with, 225-34
evacuation see defaecation
fistula repair using, 1447
interactions with other pelvic organs at efferent neural level, 203-5
irritable see irritable bowel syndrome
LUT and, similarities/differences, 474, 797
neurological disorders affecting, and associated AI, 78
neuropathic patients, bladder surgery/augmentation using, 458
non-continent cutaneous diversion risk to, 858-9
segment choice for enterocystoplasty, 850
for continent diversion, 856
SUI surgery-related damage, 1234
surgery, as FI risk, 1337-8
see also specific regions
bowel care/management and retraining programmes, 1348-50, 1375
neurogenic FI, 867-9
spinal cord injury, 907-8
stroke, 893
bowel habit/function, 1348
achieving regularity/predictable patterns, 1348
dysfunction/problems see bowel symptoms
intestinal segment removal affecting, 756
POP related to, 1096, 1097
see also constipation
bowel symptoms (bowel habit/function problems)
coexisting with urinary symptoms or UI
child, 43-5
females, 341
in FI
assessment, 1369
as FI risk factor or coexisting with FI, 1333-4, 1339-40
neurological disorders
Guillain-Barré syndrome, 911
meningomyelocele, 914-16
multiple sclerosis, 897-8
Parkinson’s disease, 888-9
spinal cord injury, 906-7
in patient-reported outcome assessment, 364-7
POP and, 285
bowel training/retraining see bowel care/management and retraining programmes
boys, nocturnal enuresis
physical examination, 720
prevalence, 714
BPH-QOL, 396-7
brachytherapy, prostate cancer, 307, 308, 1140
UI risk, 307, 308, 452-3, 1140
brain, 207-21, 225-34
in bladder control, 207-21
working models, 220-1
deep (electrical) stimulation, 827-8
gut interactions with, 225-34, 231-2
homeostatic reflexes and, 227-34
imaging see neuroimaging
magnetic stimulation, 827
see also supraspinal pathways
brain-derived neurotrophic factor (BDNF), 181-2
brain lesions, 800-1, 890-4
bladder control studies, 216
bowel dysfunction due to, 799, 800-1
FI, 862-3, 893-4, 1339
LUT dysfunction caused by/associated with, 799, 800-1, 890-3
conservative management, 811
detrusor, 258
frail elderly, 972
brainstem
bladder function and, 207-21
homeostatic emotions and, 232
lesions, and LUT problems, 892
Brazilian Foundation for Continence Promotion, 1680
Brief Index of Sexual Function for Women (BISF-W), 398
Brief Sexual Function Inventory (BSFI), 398-9
briefs see diapers
Bristol female LUTS (BFLUTS) questionnaire and short form version, 377, 378
Britain see United Kingdom
B-FAQ (Bladder Self-Assessment Questionnaire), 385
BSFI (Brief Sexual Function Inventory), 398-9
BSW (Benefit, Satisfaction and Willingness) Questionnaire, 383, 384
budget impact analysis, 1694-5
bulbocavernous muscle, innervation, 188
bulbocavernous reflex evaluation, 809
bulbourethral compression (device/procedures), 1130
historical accounts, 22, 24, 29-30
Bulkmamid, 1405
bulking agents, anal canal injection, 1403-5, 1408
bulking agents, periurethral injection, 571-2, 1209-11
children, 750-1, 843, 1236-7
cost-effectiveness, 1698-9
historical accounts, 29
men
post-prostatectomy (for benign disease), 1136
post-prostatectomy (for cancer), 1128-9
post-radiotherapy, 1139
neurogenic LUT dysfunction, 843-5
ultrasound techniques, 571-2
women with SUI, 1209-11
complications, 1236-7
see also injection
Burch colposuspension, 1197, 1294, 1295
complications, 1231
rectus fascia sling vs, 1752
sacrocolpopexy with addition of, 1754
burden disease studies, longitudinal, 1706
bypass procedures, urethral sphincter, children, 746-7

C

C-fibres/axons
neurogenic detrusor overactivity and, 258-9
non-neurogenic detrusor overactivity and, 260
vanilloid therapy and, 666-7
in spinal cord injury/lesions, urine storage abnormalities and, 224
C3 penile compression device, 1576
caeum in bladder reconstruction, see also ileocaecal valve
Caesarean delivery
AI risk, 76-8
fistula related to, 1422-4
pelvic floor injury, 267-8
POP risk, 85, 282
UI risk, 55-7, 264-5
caffeine intake (and reduction)
FI and, 1347
older people, 985
women, 1032
Cajal’s interstitial cells, 138, 139
calcitonin-gene related peptide (CGRP), 132, 177, 180
Caucasian women, epidemiology
cauda equina lesions/injury, 799, 898-9

catheters, urinary tract (predominantly urethral), 815-20, 1576-612

Catheters, rectal, 1530, 1612-14, 1616-17, 1617, 1618

Catheters, anal manometry, 475-6

Case series, 1716-17

Caregivers

CARE trial see Colpopyexy and Urinary Reduction Efforts

Catheters, anal manometry, 475-6

Catheters, rectal, 1530, 1612-14, 1616-17, 1617, 1618

Catheters, urinary tract (predominantly urethral), 815-20, 1576-612

Choices, 1578

Indwelling see indwelling catheters; suprapubic catheter

Intermittent see intermittent catheterisation

Condom see condom

in fistula repair, 1440, 1441, 1443

Neurogenic UI, 812, 815-20

Other care strategies compared with, 1606

Overall recommendations, 1610-11

Post-prostatectomy pelvic floor muscle training immediately after removal, 1083, 1084

Quality of life, 817, 1606-7, 1612

Self-management, 1609

Spinal cord lesions see spinal cord lesions

in urodynamic studies

Air-charged catheters, 419-20

Children, 467

Condom catheters, 421

Influence on voiding, 430

Caucasian women, epidemiology

POP, 83-4

UI, 53

cauda equina lesions/injury, 799, 898-9

Children, urodynamic studies, 461

Conservative treatment, 812

Cauda equina stimulation see sacral neuromodulation, anterior

Cauda equina syndrome, 908-9

Cause see aetiology

CCAAT enhancer-binding protein-homologous protein (CHOP), 148

Cells(s) for tissue-engineered graft generation, 150-1

Functional control, 151

Nutrient supply, 150-1

Support mechanisms, 150

Urethral, in visceral sensation, 171-5

Cell biology, lower urinary tract, 113-66

Celsius, Aulus Cornelius, 21

Central nervous system (and central pathways), 207-21, 634

Drugs acting on, in overactive bladder/detrusor overactivity, 670-2

Imaging see neuroimaging

LUT function and role of, 207-21, 634

Children, 726

Nocturnal enuresis and, 717-18

See also brain, brainstem; spinal cord

Cerebral cortex and bladder function, 207-21

Cerebral palsy, 800

Neurogenic detrusor-sphincter dysfunction, 741

Urodynamic studies, children, 462

Cerebral pudenl somatosensory evoked potentials, 535

Cerebrovascular accident (CVA incl. stroke), 800-1, 862-3, 890-4

FI, 862-3, 893-4, 1339, 1365

UI, 454, 800-1, 890-3

Frail elderly, 971, 973

Prognostic value of UI, 973

Cerebrovascular disease, detrusor overactivity, 258

Cervical damage in obstructed labour, 1432

Cetrotrelx, 670-1

CHAMMP (Continence, History, Assessment, Medications, Mobility, Plan) tool, 1656

Chance node (decision tree), 1692

Change, responsiveness to, in questionnaires, 366-7

Chemical stimuli, urethral role in sensing of, 173-5

Child Behaviour Check List (CBCL), 761, 762, 763, 764, 765, 767, 767-8

Childbirth (parturition incl. vaginal delivery), 264-71

FI after, 76, 288, 290-9, 354, 1334-7

Delivery technique and, 297-8, 298

Dynamic testing, 487

Episiotomy and, 269-70, 298, 1337

Training of health professionals about, 298-9

See also anal sphincter

Fistulas associated with see fistula

Patient-reported outcome assessment, 400

Pelvic floor and effects of, 264-71

levator ani, 266, 267, 565-7, 586-8

MRI, 586-8

Pathophysiological mechanisms of injury, 264-71

Prostate, 272-3, 586

Ultrasound, 565-6

Perineal trauma see perineum

POP associated with, 84-5, 282-3

Services in developing world, 1656

UI related to, 55-7, 264-71, 272-3

Pathophysiology, 264-71

Prevention, 1036-42, 1668-9

Research on, 93

Stress, 264, 265-6, 267, 272-3

Ultrasonography, 570-1

See also Caesarean delivery; delivery; instrumental delivery; labour

Children, 701-92, 1741-2

Assessment/evaluation see assessment bladder overactivity, prevalence, 74

Bulking agents, 750-1, 843

Classification of UI, 713
congenital/anatomic anomalies see congenital/anatomic anomalies
constipation see constipation
continence devices
FI, 1555-6, 1615-16
UI, 1555-6
digital rectal examination, 347
epidemiology of UI and enuresis, 38-46
behavioural disorders and, 761
day and night time enuresis, 38, 43-5, 727-8
nocturnal enuresis see nocturnal enuresis
FI, 764-6
assessment/investigations, 767
continence devices, 1555-6, 1615-16
management, 769-70, 770, 1349, 1406-7, 1408
parental impact, 766-7
psychological consequences, 764-6, 766
imaging, 709-10
intermittent catheterisation, 1579
management of UI, 718-26
non-pharmacological, 734-6
surgical, 744-59
neurogenic detrusor overactivity see neurogenic detrusor overactivity
normal (LUT) values, 704-6
parental impact, 766-7
psychological consequences of UI, 760-71
research see research
sexual abuse see sexual abuse
urodynamics see urodynamic studies
wetting see daytime and night-time wetting; enuresis; nocturnal enuresis
see also boys; girls; infants
chlordiazepoxide 0.2% (catheter maintenance solution), 1598
cholera toxin B-labelling of levator ani motor neurones, 197
cholinergic drugs, neurogenic UI, 825
cholinesterase inhibitors, UI risk
Alzheimer’s disease, 878
elderly, 682, 983
chondroitin sulfate, intravesical/intramural, in bladder pain syndrome, 1487
CHOP, 148
chronic pelvic pain see pelvic pain
cigarette smoking see smoking
cimetidine, bladder pain syndrome, 1483
cingulate gyrus and cortex, anterior (ACG), 217, 221
imaging, 606
circumcision, female, 1424
circumferential fistulas, 1445
cisapride in FI, 1352
neurogenic patients, 868
Parkinson’s disease, 890
clam cystoplasty, 849
clamps, penile, 1575, 1576
historical accounts, 29-30
cleaning/cleansing
commodes or bedpans, 1536
intermittent catheters, 1583-4
skin, 1622-4
clenbuterol
overactive bladder, 658
SUI, 673
clinical data, baseline, ICS Standardization Committee recommendations, 1730
clinical trials see trials
clinicians observations in research, ICS Standardization Committee recommendations, 1731
cloacal extrophy, 745
Clostridium difficile-associated diarrhoea, 1347, 1366
management, 1372
coatings
indwelling catheter, 1589, 1593, 1594, 1596, 1597, 1602
intermittent catheter, 1580, 1581
cognitive-behavioural therapy, children, 769-70
cognitive impairment (intellectual impairment)
antimuscarinic-induced
darifenacin, 649
elderly (incl. frail persons), 681-2, 982, 993, 994
oxybutinin, 655
FI risk, 1338
UI risk with (especially elderly), 970-2, 983
in Alzheimer’s disease, 877, 878
drug-related, 982
men, 69
research, 1749
women, 59-60
see also learning disability
cognitive modulation of brain responses to visceral stimuli, 232
cohort studies of SUI surgery, 1751
coitus see sexual intercourse
cold sensation tests see ice water/ test; thermal testing
colecystectomy, FI risk, 1337-8
colitis, ulcerative, and FI, 1334
collagen, 133-4
analysis, 627
POP and abnormalities of, 280-1
porcine dermal see dermal collagen
subtypes, 133-4
collagen injections, anal canal, 1403, 1404, 1405
collagen injections, periurethral (as bulking agent)
children, 750
men
post-prostatectomy, 1129
post-radiotherapy, 1139
neurogenic LUT dysfunction, 843, 844
women with SUI, 1209
complications, 1237
colostomy, 877, 1405-6, 1408
antimuscarinic-induced
darifenacin, 649
oxybutinin, 655
elderly (incl. frail persons), 681-2, 982, 993, 994
in Alzheimer’s disease, 877, 878
drug-related, 982
men, 69
research, 1749
women, 59-60
see also rectosigmoidoscopy; sigmoid resection; uterosigmoidostomy
colostomy, 877, 1405-6, 1408
rectourethral fistula, 1153, 1154, 1155, 1156
colpectomy, 1292
Colpexin Sphere device, 1102, 1103
colpopexy, 1102, 1103
colpopexy, surgical, 1294-59
concomitant continence procedure, 1299
colpopexy, surgical
sipradox see sacrocolpopexy
sacrospinosus see sacrospinous ligament suspension or colpopexy
Colpopexy and Urinary Reduction Efforts (CARE) trial, 448, 1279, 1286, 1287, 1294, 1754
outcome assessment, 1276, 1277, 1754
colporrhaphy
anterior, 1195-7, 1288, 1289
augmenting materials, 1300
posterior, 1289, 1290, 1291
colposuspension, 1197-8, 1294-5
concomitant to other surgical procedures, 1295, 1754
historical accounts, 29
laparoscopic, 1205-9
cost-effectiveness compared to open colposuspension, 1208, 1698-9
mid-urethral tapes vs, 1218
Burch see Burch colposuspension
cost-effectiveness compared to laparoscopic colposuspension, 1208, 1698-9
Marshall-Marchetti-Krantz procedure vs, 1202
mid-urethral tapes vs, 1218
for recurrent SUI, 1225
sling procedures vs, 1212
rectus fascia sling vs, 1752
tension-free vaginal tape compared with, 1752, 1753
comfort


drainage bags, 1562
indwelling catheters, 1600
pads, 1556
commodes, 1526, 1535-7
communication, continence promotion programmes, 1649
community
absorbent bodyworn products in, evaluation, 1550, 1551
acute or subacute care to, 1656
fistula prevention in, 1436
comorbid and pre-existing medical conditions
bladder dysfunction and, 225
FI associated with, 78, 1333-4, 1338-9, 1340, 1365-6, 1367-70
frail elderly with UI, 970-5, 983
research, 1739
role in management, 978, 1000
nocturnal enuresis and, 42

POP associated with
see pelvic organ prolapse
see also specific methods
congenital/anatomic anomalies
anorectal see anorectum
CNS, 459-61, 741, 912-16
colic aganglionosis (Hirschsprung’s disease), 138
LUT, 463-5
surgery, 745, 1153
connective tissue
diseases, and POP, 280
injury in childbirth, 266

inquiry related to, 282
conscious perception of input from body as aspects of homeostasis, 230-1
consent, informed see informed consent
conservative/medical management
FI, 1341-50, 1353-61
frail elderly, 1370-3
meningomyelocle, 914-15
neurogenic, 867-70
surgery with failure of, 871
fistulas in women, 1437-9
outpatient, economic analysis, 1700-2
research see research
surgical vs, decision tree, 1692
UI and LUT problems, 811-29, 1025-120
historical accounts, 23
men, 1082-95, 1108
neurogenic LUT dysfunction, 811-29
older people see older people
trials see trials
women, 1027-82, 1107-8
women with non-obstetric fistulas, 1249
women with POP, 1095-107, 1108

see also specific methods

consistency, internal, questionnaires, 366
Consolidated Standards of Reporting Trials see CONSORT
CONSORT statement/guideline, 1718, 1726, 1727-8, 1749, 1751,
1752, 1753
flow diagram, 1726, 1728, 1749, 1752
constipation, 1334
assessment and quantification
children, 708
older people, 1367-9
children, 42, 765
with enuresis, 43
management, 770
quantification, 708
FI due to see overflow FI
neurological patients
dementias, 882-3
drug therapy, 868
spinal cord injury, 862
women with
effect of lifestyle interventions on UI in, 1033
POP and, 82, 283, 1096, 1097
content validity of questionnaires, 366
Contilife®, 378
continence
advocacy, 1652-8
age-related changes affecting, 966
awareness, promotion, 1645, 1646-58
preventive aspects, 1666-7
factors maintaining, 137
oestrogens, 676
males
mechanisms, 300-2
post-prostatectomy recovery, 306
organisations see organisations
POP surgery combined with treatment of, 1294-5
post-fistula closure, status, 1449
continence gap, 1448
in sneezing, neural mechanisms, 194
urethral reconstruction to achieve, child, 752-3
Continence Action Society (Japan), 1650, 1665, 1681
Continence Association
Danish, 1680
New Zealand, 1681
South Africa, 1682
continence care see care
Continence Care Pathways, 1662
continence centre (L-region), pontine, 212, 220
control, 127
spinal cord injury, 901

cutaneous care/problems etc. see skin

cutaneous continence urinary diversion, 856

cyclo-oxygenase inhibitors see non-steroidal anti-inflammatory drugs

cyclosporine, bladder pain syndrome, 1483-4

cystectomy
radical, neobladder following see neobladder
subtrigonal and cystoplasty in bladder pain syndrome, 1494
supratrigonal see supratrigonal cystectomy
and urethrectomy, urinary diversion with/without, in bladder pain syndrome, 1494

cytisitis (bladder inflammation)
interstitial see bladder pain syndrome
reduced bladder capacity in, 1151
cystocele see vaginal wall prolapse, anterior
cystostension (hydrostension; overdistension), 1237-8
in bladder pain syndrome, 1477, 1502-3
in chronic pelvic pain, 1492
cystolysis, bladder pain syndrome, 1492

cystometrical capacity, maximum, child, 712

cystometry, 419, 426-30
adjuncts to, 440
bladder pain syndrome, 1475
bladder sensation assessment during, 534
filling see filling cystometry
frail elderly, 470, 471
neurogenic LUT dysfunction, 804-6
normal values, 426-30
spinal cord injury, 900
voiding, 419

cystopathy, diabetic, 916-17
cystoplasty (bladder reconstruction/augmentation/enlargement - reservoirs, pouches etc.), 747-50, 849-55, 1239-40
in bladder pain syndrome, 1493-4
children, 747-50
in neurogenic dysfunction, 458, 459
psychological consequences, 759
techniques, 748-9
in detrusor overactivity, 1239-40
complications, 1242
fistulas (non-obstetric), 1251
in neurogenic dysfunction, 849-55
children, 458, 459
see also auto-augmentation; neobladder
cystoscopy see endoscopy
cystotomy, continent, 855-6
cystourethrography, voiding (VCUG), 550
child, 710-11
with daytime and night-time wetting, 466
combined with urodynamics see videourodynamic
female, 551-7
methodology, 551-9
non-obstetric fistulas, 1248, 1249
urethral diverticulum, 1246
see also urethrography
men, preoperative, 1124
other imaging methods compared, 557, 593
cystourethropexy, historical accounts, 29
cystourethroscopy see endoscopy
cytology, urine, males, 352
Czech Republic, continence organisation, 1680

D

da Vinci, Leonardo, 22
Dacron® -reinforced silicon sling, 1212
Daily Living Self Management Project (Australia), 1697
Danish Prostatic Symptom Score (DAN-PSS), 377, 378
darifenacin, 648-50, 822, 1703
adverse effects, 649
everly, 682, 994
economic analysis, 1703
everly, 994
adverse effects, 682, 994
dartos flap, 1160
data
baseline clinical and demographic, ICS Standardization Committee recommendations, 1730
collection, in trials, mistakes, 1719
interpretation/analysis, 1725-7
intention-to-treat vs per-protocol approaches to, 1724-5
mistakes, 1719
quality, transient UI in older people, 309

Data Safety Monitoring Board, 1722, 1757
daytime and night-time wetting, co-existent (non-monosymptomatic nocturnal enuresis), 38, 43-5, 726-40, 761, 763-4
assessment, 728
causes/risk factors, 761
classification, 729-34
confounding factors, 728-9
epidemiology, 38, 43-5, 727-8, 761
prevalence, 727-8
therapy, 734-40
voiding cystourethrography, 466
daytime frequency (=frequency of daytime micturition), measuring, 336
daytime frequency (=frequent micturition), definition, 334-5
daytime wetting (diurnal enuresis), 763-4
bladder training, 1078
bowel problems and, association between, 43-5
night-time and see daytime and night-time wetting
risk factors and causes, 45-6
urodynamic studies, 465-6
DDAVP see desmopressin
deaths/mortalities
enterocystoplasty, 850
obstetric fistula-related, 1446
SUI surgery-related, 1236
decision analysis, 1691-4
decision tree, 1692-3
decompression surgery, lumbar disc prolapse, 912
decubitus (pressure) ulcers, 1620-1
dep deep brain stimulation, 827-8
defaecating proctography see defaecography
defaecation (bowel/rectum evacuation)
assistive techniques, 868-9, 1349
forces, 500
inappropriate see faecal incontinence
physiology/mechanism, 137
reflex-triggered, 868
by mechanical stimulation, 867, 867-8
training, 1349
urgency see urgency
defaecography (defaecating/evacuation proctography), 612
in POP, 285
definitions and terminology, 334-5
bladder pain syndrome, 1461-2, 1464-6, 1503, 1745
evuresis, 38-46
nocturnal, 38-9, 713
in epidemiological studies, 38
differing/varying, 86-7, 93
female UI, 46, 47
FI, 1323
frailty, 964
male UI, 65
POP, 1746, 1747
storage symptoms, 334-5
degenerative joint disease, frail elderly, 971
definibulation, 1424
delirium, older people, 309
delivery, fistula numbers per 1000 deliveries, 1426
see also Caesarean delivery; childbirth; instrumental delivery
Delorme procedure, 1307-8
dementia, 877-83
constipation and FI associated with, 882-3, 1338, 1365
caregiver education in prevention of, 1342-3
treatment, 1371
LUT problems/UI risk, 800, 877-82, 970-2
with cholinesterase inhibitors, 682, 983
men, 69
women, 59, 60
demographic data
baseline, ICS Standardization Committee recommendations, 1730
frail older and disabled people with UI/LUTS, 1739
denervation (pathological) see nerve injury
denervation (technique)
in bladder pain syndrome, 1493
in detrusor overactivity, 838-42
women, 1238-9
Denmark, continence organisation, 1680
depression (and LUT dysfunction), 225, 1668
spinal cord injury, 902
SUI surgical outcome in, 1224
UI risk, 60, 1668
frail elderly, 971, 972-3
dermal collagen, porcine
anal canal injection, 1405
sub-urethral sling made from, 1216
dermatitis, perineal/incontinence-associated, 1618-26
dermatology see skin
dermatomes, lower spine, 803
descending pathways/tracts
anal and urethral rhabdosphincters and, 189
homeostatic reflexes and feelings and, 231, 233-4
descriptive epidemiology, 37
desipramine, bladder pain syndrome, 1483
desmopressin (dDAVP), 679-81
nocturia, older people, 1001
nocturnal enuresis, 721-2, 771
alarm, 725
non-responders, 725
detrusor (bladder wall smooth muscle)
activation and contraction see contractile properties; contraction biomechanics, 132-7
botulinum toxin A injection, 661, 662, 663
compliance see compliance
EMG in neurogenic LUT dysfunction, 808-9
hyperreflexia see neurogenic detrusor overactivity
ion channels, 122, 144
myectomy/myotomy see auto-augmentation
overactive see detrusor overactivity
preoperative functional assessment, men, 1125
relaxation, 123
urethral sphincter contraction and, disorders of see detrusor-sphincter dysfunction; detrusor-sphincter dyssynergia
strengthening surgery, 838
underactive see underactive bladder
urothelial/suburothelial interactions with, 120
see also smooth muscle, bladder wall
detrusor overactivity (hyperreflexia), 429, 434-8, 639-72, 1145-9, 1237-45
bladder training, 1075
children, 726, 727, 730, 742
neurogenic see neurogenic detrusor overactivity
nocturnal, 717
resistance to therapy, 744
and underactive sphincters, 742, 744
definition of outcome in women, 1738
diagnosis, 434-40
distinguishing and defining characteristics, 438-9
drug therapy see drug therapy
electrical stimulation, men, 1088, 1089-90, 1149
electrical stimulation, women, 1060, 1061, 1062, 1063, 1064, 1065
and/or pelvic floor muscle training, 1066
filling cystometry, 434-6
idiopathic, 664-5
botulinum toxin A, 664-5
men, management, 1145-9
resiniferatoxin, 667-8
incontinence due to, 434
urodynamic studies, 434-5
magnetic stimulation
demyelination
in Guillain-Barré syndrome, 801, 909-11
in multiple sclerosis, 801
diaphragms, intravaginal bladder neck-supporting, 1572-3
diabetes mellitus, 801, 916-17, 1667
children, and nocturnal enuresis, 42
FL, 917, 1339, 1365
UI, 801, 916-17
frail elderly, 971
lifestyle management of weight, 1029
risk, 1667
risk, women, 58
Diabio®, 836
diacylglycerol (DAG), 128, 129
diagnostic tests
children, 707-12
invasive, 710-12
non-invasive, 707-10
neurogenic FL, 864-6
diabetic UI see neurogenic LUT dysfunction
screening tools see screening urodynamic studies as, 433, 434-40
see also assessment; investigations
diamorphine, chronic pelvic pain, 1491
diaper(s)/briefs (adult/all-in-ones), 1540, 1553
frail elderly, vs other methods, 979-80
with superabsorbent polymers, 1621-3
diaphragms, intravaginal bladder neck-supporting, 1572-3
men, 1145
women, 1065
men, 1145-9, 1161
electrical stimulation, 1088, 1089-90, 1149
idiopathic, 1145-9
men, surgery, 1149
older men, 1138
neural mechanisms, 222-4
see also neurogenic detrusor overactivity
non-neurogenic, 259-64
in normal subjects, 429
pathogenesis, 636
and sphincter underactivity/areflexia, 812
children, 742, 744
conservative management, 812
in spinal canal stenosis, 909
SUI surgical outcome in patients with, 1226-7
surgery, 1237-45
complications, 1242-5
denervation procedures, 838-42
men see subheading above
women, 1237-45
urodynamic studies, 434-8
men, 450-1
therapeutic response prediction, 441-2
see also overactive bladder
detrusor pressure measurement, neurogenic LUT dysfunction, 804
detrusor-sphincter dysfunction, neurogenic, children, 740-4
detrusor-sphincter dyssynergia
children, 742
EMG, 532
spinal cord injury, 901
treatment, 904
surgery, 833
urodynamic studies, 456
Deutsche Kontinenz Gesellschaft e.V., 1680
developing world
obstetric fistula see fistula
services in, 1656
development at bladder/sphincter control, 703-4
delayed
and daytime enuresis, 45
and nocturnal enuresis, 42
developmental reflexes in Alzheimer’s disease, 878
devices see continence devices
dextranomer-hyaluronic acid co-polymer see hyaluronic acid-dextranomer co-polymer
diabetes mellitus, 801, 916-17, 1667
children, and nocturnal enuresis, 42
FL, 917, 1339, 1365
UI, 801, 916-17
frail elderly, 971
lifestyle management of weight, 1029
risk, 1667
risk, women, 58
Diabio®, 836
diacylglycerol (DAG), 128, 129
diagnostic tests
children, 707-12
invasive, 710-12
non-invasive, 707-10
neurogenic FL, 864-6
diabetic UI see neurogenic LUT dysfunction
screening tools see screening urodynamic studies as, 433, 434-40
see also assessment; investigations
diamorphine, chronic pelvic pain, 1491
diaper(s)/briefs (adult/all-in-ones), 1540, 1553
frail elderly, vs other methods, 979-80
with superabsorbent polymers, 1621-3
diaphragms, intravaginal bladder neck-supporting, 1572-3

1833
DIAPPERS mnemonic, 977

diarrhoea and loose stools, 1333-4
FI associated with, 78, 1333-4
drug therapy, 1350-1
frail elderly, 1356, 1372
reversible causes, 1366

Dieffenbach, Johann Friedrich, 26

dietary factors (and dietary modification), 1031-3

bladder pain syndrome, 1481
FI, 354, 1340, 1343-8, 1374-5
UI, 1667

women, 61, 1031-3

diffuse noxious inhibitory control (DNIC) systems, 233
digital examination/palpation in FI, 355
diagnostic/rectum
anal resting pressure and, comparisons of measurement of, 480
old people, 1369
voluntary squeeze pressure and, comparisons of measurement of, 484-5
pelvic floor muscles, 348
rectum

digital rectal stimulation, 867-8
dimethylsulfoxide, intravesical, in bladder pain syndrome, 1486-7
diphenoxylate, 1350-1
dipstick urinalysis, 337-8

males, 352
disabilities
physical see functional impairment
research on people with, 1739-41

disc (intervertebral) disease, 801
discounting in cost-utility analysis, 1696
discrete probability distribution, 1694
discretion, pads, 1557
disease see comorbid and pre-existing medical conditions
disposable absorbent products
bodyworn, 1539, 1540, 1541, 1543, 1544, 1550-4
intravaginal bladder neck-supporting devices, 1573, 1574
light UI, females, 1544, 1545, 1546
light UI, males, 1546, 1548, 1549
moderate/heavy UI, 1550-4
underpads see underpads
distributions (statistical), 1694
diuresis, old people, 311
diurnal enuresis see daytime wetting
diverticula, urethral (women), 603, 968, 1245-7
diagnosis/investigations, 968, 1245-7
diagnostic/ investigations, 968, 1245-7
imaging, 603, 1245-6
examination for, 344
treatment, 1246-7
DMSO, intravesical, in bladder pain syndrome, 1486-7

doctors/physicians
advanced practice nurses and, collaboration in care of frail elderly, 1004
family/primary care see primary care
see also health care staff; surgeons
domperidone, 890
donepezil, 878
dopamine and bladder function, 213-14
dopaminergic agents in Parkinson’s disease, 998
dorsal clitoral nerve, electrical stimulation, 535
dorsal penile nerve, electrical stimulation, 535
dorsal root entry zone rhizotomy, 839
dorsal sacral root rhizotomy, 839
double balloon urethrography, diverticulum, 603, 1246
double blind trials, 1716, 1722-3
doxepin, bladder pain syndrome, 1483
drainage bags, 1561-7
for indwelling catheters, 1564-6, 1602, 1608
males, 1529
DREZotomy, 839

dribble
containers/pouches (males), 1528, 1567
post-micturition
definition, 335
pelvic floor muscle training for, men, 1087
rarity of UI in young/middle-aged men due to causes other than, 1737
urodynamic studies in men, 455
terminal
definition, 335
urodynamic studies in men, 455
drug-disease interactions in frail elderly, 983
drug history, frail older and disabled people, research, 1739
drug-induced incontinence
AI, 1340, 1342
reversibility, 1366
UI
Alzheimer’s disease patients, 878
older people, 309-10, 682, 973, 974
drug therapy, 631-99, 1750-1
benign prostatic obstruction, frail elderly, 1001
bladder pain syndrome, 1481-8
refractoriness, recommended management, 1502, 1503
children, 736-40, 771
neurogenic UI/bladder, 459, 664, 739, 742, 743
nocturnal enuresis see subheading below
chronic pelvic pain, 1490-2
day and night-time enuresis, 729
detrusor overactivity/overactive bladder symptoms, 639-72, 1075
children, 736-9
men, 1146
FI, 1350-2, 1375
multiple system atrophy, 886
neurological patients with constipation, 868
older people, 1371
Parkinson’s disease, 890
spinal cord injury, 907-8
historical accounts, 23
hormonal see hormone therapy
multiple system atrophy, 884-5
neurogenic UI/bladder, 643-5, 661-8, 820-5
as adjunct to catheterisation, 816
children, 459, 664, 739, 742, 743
Parkinson’s disease, 887
spinal cord injury, 903-4
nocturia, 679-81
frail elderly, 1000-1
nocturnal enuresis, 679, 721-3, 771
non-responders, 725
novel molecular targets in LUT, 140-9
older people (incl. frail persons), 681-2, 981-3, 989-95, 1740
adverse effects, 681-2, 982-3, 993, 994
benign prostatic obstruction, 1001
diapers vs, 979-80
FI, 1371
nocturia, 1000-1
recommendations, 1007, 1008
research, 1740
overactive bladder see overactive bladder
overflow incontinence, 676
SUI see stress incontinence
trials/research, 1718, 1750-1
adherence to design criteria, 1755
aiding economic evaluation, 1704, 1705
categories, 1718
FI, 1352, 1375
older people, 1740
women, 1076
bladder training vs, 1074-5, 1075
bladder training with, 1076
electrical stimulation vs, 1065
Elastin, vaginal and supportive tissues, alterations in POP, 280-1
Egyptians, ancient, 21
Dryness, children, bladder outlet reconstructions for, 753
Duloxetine, 660
Dry bed training, 723-4, 770
Dry expectations project, 1651

Pelvic floor, men, 1088-91, 1149
Pelvic floor (in general), 828
In neurogenic UI, 826-9
Neurogenic FI, 869-70, 871-2
Historical accounts (=electrotherapy), 24

Electrical stimulation (and neuromodulation), 526, 810, 812, 826-9,
education and support, 1651
Efferent neurones, 1651

Electrocoagulation, non-obstetric fistulas, 1249
Electrodiagnostic tests see neurophysiological studies
Electrofulguration, non-obstetric fistulas, 1249
Electrolyte disturbances, intestinal reservoir-related disturbances,
755-6

Electron microscopy see ultrastructure
Electroneurography, sensory, 534

Electronic Pelvic Floor Symptoms Questionnaire, 392-3
Elephantiasis, 865-7, 866
Encopresis, 765
Encrustation, indwelling catheter, 1596-9
Endovascular cushions, anal, 286
Endoplasmic reticulum, stress response, 146-8

Endoscopy, 609
Imaging, 548
Surgery, 745-6
Ectopic ureterocele see urethral diverticulum

Economic issues see cost
Ectopic ureter
Endoscopy, 609
Imaging, 548
Surgery, 745-6
Ectopic ureterocele see urethral diverticulum

Education and support
Caregiver, FI, 1342-3, 1373
Patient
Bowel training see bowel care
Intermittent catheterisation, 1583, 1584
Patient, FI prevention, 1342-3, 1374
Older people, 1373
Professional see health care staff
Public/consumer, 1646, 1649-50, 1650-1, 1657-8
See also information
Efferent neurones see motor neurones

Egyptians, ancient, 21
Elastin, vaginal and supportive tissues, alterations in POP, 280-1
Childbirth and, 282
Elderly see older people
Electrical properties
detrusor, 122
Urethral smooth muscle, 127

Electrical stimulation (and neuromodulation), 526, 810, 812, 826-9, 1058, 1242-5
Bladder see intravesical electrical stimulation
Children, 735-6
Complications see safety aspects
In detrusor overactivity see detrusor overactivity
Dorsal penile/clitoral, 535
Fl, 1359-60, 1376, 1394-6, 1399-403
Neurogenic, 869-70, 871-2
Of transposed muscles (=dynamic/stimulated muscle transposition), 873, 1394-6, 1408
Historical accounts (=electrotherapy), 24
Neurogenic Fl, 869-70, 871-2
In neurogenic UI, 826-9
With spinal cord lesions, 812, 904
Pelvic floor (in general), 828
Pelvic floor, men, 1088-91, 1149
Future research directions, 1095
older people, 1371
Enhancing the QUAlity and Transparency Of health Research (EQUATOR) Network project, 1718, 1720
enlargement cystoplasty see cystoplasty
enteric nervous system
enteric reflexes, 227
Parkinson’s disease, 889
enterocystoappendectomy see bowel
enterocystoplasty see bowel
enuresis (wetting), 38-46
diurnal/daytime see daytime wetting
epidemiology see children
evaluation see assessment
nocturnal see nocturnal enuresis
parental impact, 766-67
psychological consequences for child, 760-4, 766-71
therapy, 718-6
non-responders, 725
enuresis alarm, 725, 770
day time, 736
desmopressin and, 725
non-responders, 725
Enuresis Resource and Information Centre (ERIC), 1682
environmental factors associated with UI in frail elderly, 972, 975
EPI (Estimated Percent Improvement), 384
epidemiology, 35-111
AI/FI, 73-9, 1323-41
child, 764
frail elderly, 1362, 1365
research recommendations, 93-4
analytical, 37
basic considerations, 27-8
bladder pain syndrome, 1463-9, 1502
clinical work, important differences between, and their implications, 88-9
Descriptive, 37
enuresis see children
neurological diseases causing UI or FI see specific diseases
overactive bladder see overactive bladder
UI (in general), 38-72
children see children
men, 64-72, 349-50
neurogenic, 69, 799-802
research, and recommendations, 64, 92-3
women, 46-64
worldwide estimates of numbers of individuals with UI, 89
worldwide estimates of numbers of individuals with LUTS, 89
see also specific epidemiological parameters e.g. prevalence; risk factors
Epidemiology of Prolapse and Incontinence Questionnaire (EPIQ),
378
epidermoid carcinoma and multiple sclerosis, 895-6
epididymo-orchitis, spinal cord injury patients, 902
epidural analgesia, labour, 268-9
epidural recording of evoked spinal cord potentials, 810
EPINCONT study, 1030, 1032
EPIQ (Epidemiology of Prolapse and Incontinence Questionnaire), 378
episiotomy, 269-70, 298, 1337, 1668
developing countries, 1424
epispadias, 745, 1142-5
surgery for persisting incontinence (later life), 745, 1142-5
epithelium
Na* channels see sodium ion channels
transitional see urothelium
see also mucosa
EQ5D, 1696
EQUATOR Network project, 1718, 1720
equivalence trials, 1717-18
erectile dysfunction (impotence)
International Index of, 396
PDE5 inhibitors, 659
ERIC (Enuresis Resource and Information Centre), 1682
catheters
mesh (in sacrocolpopexy), 1279
urethral see urethra
Escherichia coli, uropathogenic, 117, 171
essential tremor, 827
ESSIC (European Society for the Study of Interstitial Cystitis), 1464, 1465, 1476, 1492, 1503
Estimated Percent Improvement (EPI), 384
estrogens see oestrogens
ethical considerations, 1756-8
fistula surgery, 1451-2
in research, 1756-8
equality see race
European Pressure Ulcer Advisory Panel (EPUAP), 1620, 1621
European Society for the Study of Interstitial Cystitis (ESSIC), 1464, 1465, 1476, 1492, 1503
EuroQol EQ5D, 1696
evacuation see defaecation
evaluation (of patients and their conditions) see assessment
evoked potentials, 525
bulbocavernosus reflex, 809
correlation with biology, 525
motor, 533, 809
somatosensory, 534-5, 810
spinal cord, epidural recording, 810
examination, physical see physical examination
excitatory mechanisms, peripheral, 205-7
exclusion criteria in trials, 1721-2
common mistakes, 1719
exercise (therapeutic)
in FI treatment and prevention, 1341, 1343, 1353-9, 1374
in pad testing, 618, 620, 623
pelvic floor see pelvic floor muscle training
toileting combined with, frail elderly, 985
see also physical exercise
expectation of aversive visceral stimuli, 232-3
explanatory trials, 1724-5
exstrophy
bladder see bladder, exstrophy
cloaca, 745
extended-release formulations
oxybutinin, 646-7, 654-5, 1704
naphazoline, 646-7
fistula surgery, 1451-2
see also pelvic floor muscle training
vestibular, 646-7, 648
external devices/appliances see continence devices
extracellular matrix, pelvic floor-supporting tissues, 627, 628
extra-urethral occluding devices
female, 1567-70
male see males

F
facial incontinence (anal incontinence), 285-99, 475-500, 1321-86,
1612-18, 1707-8, 1744-5
assessment
initial, 353-5
in neuropathic patients, 864-6
older people, 1367-70
of symptoms and QoL impact, 393-4, 866
causes/risk factors see aetiology
definitions, 1323
obstetric (predominantly developing world), 24-7, 1419-58
aetiology and epidemiology, 1422-9
conservative management, 1437-9
development, 1422-4
diagnosis, 1429-35
organisation of care, 1450-2
predisposing factors, 1426-9
prevention, 1435-6
simple, 1439-44, 1452, 1453
surgery see surgery
flap(s)
rectourethral fistula repair, 1440, 1442, 1444, 1446, 1447
muscle transposition see muscle transposition
flatus incontinence, 353
odour control, 1626, 1627
flavoxate, 657, 821-2
frail elderly, 993
and emepronium, 991, 995
and propantheline, 992, 995
flow see urine flow
fluid intake (and its management), 1667
FI and, 1343-8, 1374-5
older people, management, 985
women, 1033
flurbiprofen, frail elderly, 992, 995
follow-up in trials, 1734
time, 1725, 1734
Fondazione Italiana Continenza, 1681
footdrop, 1434
force(s), defaecation, 500
forceps delivery, trauma, 297-8
forebrain interoceptive representation, 231
four-dimensional ultrasonography, 559
frail elderly persons, 468-73, 961-1024, 1362-73
aetiology of UI, 965-75, 1009, 1739-40
assessment see assessment
definition of frailty, 964
FI, 1362-73, 1376
impact of UI on morbidity and institutionalisation, 964-5
LUT dysfunction, outcome measures, 1740
management of UI, 977-97, 1010-12
algorithm, 1010-12
factors in, 977-84
models of care, 1001-5
pharmacological see drug therapy
recommendations, 1005-9
special issues, 983-4
surgical see surgery
nocturia see nocturia
prevention of UI, 1669-70
research see research
urodynamic studies, 468-73, 977
France
continence awareness and promotion, 1651
continence organisation, 1680
Frank (German doctor in 1882), 27
frequency (=frequency of micturition), measuring, 336
frequency (=frequent micturition)
daytime, definition, 334-5
see also urgency/frequency
frequency/volume chart (bladder chart)
children, 707-8
nocturnal enuresis, 719
frequency/volume diary (bladder/voiding diary), 337, 1733, 1734
children, 706, 707
neurogenic LUT dysfunction, 802
women, postoperative (after UI surgery), 1253
frontal lobe, in bladder control, 216-17
frontotemporal dementia, 881-2
fructose, dietary, 1347
Frykman-Goldberg operation, 1308-9
FSFI (Female Sexual Function Index), 397-8
full spectrum home training in nocturnal enuresis, 770-1
functional brain imaging, 583
bladder control studies, 216-20
visceral stimuli, 231-3
functional control of tissue-engineered grafts, 151
functional disorders of LUT see lower urinary tract dysfunction
functional FI, older people, 1365
functional impairment (mobility restriction; physical disability)
FI risk, 1331
research, 1739
UI risk
men, 69
older people, 311, 972, 973-5
women, 59, 64
functional incidental training, 986
functional outcomes, enterocystoplasty, 853
functional status in FI, assessment, 354
functional UI, children
classification, 713
prevalence, 42-5
funding, fistula care in developing world, 1450

G

G-proteins and G-protein coupled receptors, 140, 142, 637
GABA (gamma-aminobutyric acid - and its receptors), 201
GABAB receptors, 142, 194
gonadotropin releasing hormone (GnRH) agonists in detrusor overactivity, 668-70
urethral and anal sphincters, 194
gabapentin
bladder pain syndrome, 1481
chronic pelvic pain, 1491
UI, 671
-galactosidase, oral, 1627
Galen, Claudius, 21
gamma-aminobutyric acid see GABA
ganglia, bladder and, 198-200
gastric augmentation see stomach
gastrointestinal tract (gut)
brain interactions with, 225-34, 231-2
disorders, intestinal segment removal causing, 756
in FI, 285-90
lower see bowel
reconstruction using see neobladder
research recommendations, 151
see also specific regions e.g. bowel
Gellhorn bivestry, 1102, 1103, 1104, 1105, 1106
gender (sex)
AI and, 74
care-seeking behaviour and, 1647, 1648
continence devices and, 1525
body worn absorbent, 1552
nocturnal enuresis and, 41, 715
see also females; males
general anaesthesia for POP vs local anaesthesia, 1707
general practitioners see primary care
genetic factors (in disease)
bladder pain syndrome, 1471
nocturnal enuresis, 714-15
POP, 83, 84, 280
UI, women, 61, 64, 65, 83
SUI, 275-6
genital herpes, 801
genitalia/genital organs
afferent projections to spinal cord, 182-4
female
injury in obstructed labour, 1431-3
mutilation, 1424-5
physical examination, 342
prolapse see pelvic organ prolapse

see also gynaecological surgery
genitourinary fistula see fistula
geographical distribution of obstetric fistulas, 1422
geriatric syndrome, UI as, 965
see also older people
Germany, continence organisation, 1680
Gersuny R, 27
giggle incontinence, 732-3, 764
girls
bladder reconstruction and future pregnancy, 758
fistula surgery, 746
nocturnal enuresis
physical examination, 720
prevalence, 714
vesicovaginal entrapment, 733
gishiri-cutting, 1424
glial cells, spinal cord, 183
glial fibrillary acidic protein (GFAP), 184
global assessment scales in women after UI surgery, 1254
Global Perception of Improvement (GPI), 384
Global Response Assessment, 1498
glucose-regulated protein (GRP78), 148
glucosuria, 337
glutamate
micturition and role of, 183
urethral and anal rhabdosphincters, 194

glomerulonephritis, 794

Guillain-Barré syndrome, 801, 909-11

Gore-Tex® for slings, 1212-15
GPI (Global Perception of Improvement), 384
GPs see glycoproteins; primary care

gracilis muscle flaps in FI, 1394-6
artificial anal sphincter vs, 1398
dynamic/stimulated, 873, 1394-6
neurogenic FI, 873
grafts, 149-51


see also specific modalities
imipramine
frail elderly, 991
nocturnal enuresis, 723
overactive bladder symptoms/detrusor overactivity, 660
SUI, 674-5
IMMPACT recommendations, 1501, 1501
immunosuppressants, bladder pain syndrome, 1483-4
IMMPACT study, 647
imperforate anus, 462-3
IMPACT study, 647
incontinence
see also erectile dysfunction
incidence
AL, 74
definition, 38
POP, 80-2
UI
men, 65
women, 53-5
inclusion criteria in trials, 1721-2
common mistakes, 1719
Inco Forum
Czech Republic, 1680
Poland, 1681
Slovakia, 1682
indwelling catheters, suprapubic, 819-20, 1578, 1588, 1589, 1606
indwelling catheters, transurethral (and in general), 818-20
intermittent catheters, 1584-5, 1586-60, 1610
catheter characteristics, 1588-9
urethral/periurethral
anal canal, 1403-5, 1408
rectourethral, 1153-4
levator ani
iatrogenic
urothelium in, 117
nerve injury (predominantly traumatic/mechanical)
bladder
in obstructed labour, 1429-30
in SUI surgery, 1232-3
brain, FI, 863, 1339
cauda equina, see cauda equina lesions
childbirth-related, see childbirth
fistula due to
obstetric, 1422-5, 1429-31
rectourethral, 1153-4
iatrogenic
levator ani
MRI, 838-6
ultrasound, 565-7, 571
nerves, see nerve injury
pelvic floor
urethral
incontinence after, men, 1141-2
in obstructed labour, 1431
with indwelling catheters, 1599
with intermittent catheterisation, 1582-3
with obstructed labour, 1430-1
with SUI surgery, 1232
urothelial response to, 170-1
vaginal, with obstructed labour, 1431-2
Inco Forum, 1680
innervation
see also nerve supply
inositol trisphosphate (IP3), 128, 142-9
inserts
external (liners; shields), 1538-40
light UI, females, 1545, 1547
light UI, males, 1548, 1549
moderate/heavy UI, 1550, 1551, 1552, 1553
urethral, 1570-2
institutional care (elderly)
see also nursing home
instrumental delivery, 297-8
intravesical drugs and chemicals (transvesical instillation/injections), intravenous urography/pyelography, intravaginal sling procedure, intravaginal devices, intravesical pressure (bladder pressure) in bladder pain syndrome, 1488

in pelvic floor injury, 267
pelvic organ prolapse associated with, 282
insula, 217-19, 226, 227, 230, 231

intestinal impairments see cognitive impairment
intelligence tests, 768
intention-to-treat, 1724, 1725
intravesical catheterisation (incl. self-catheterisation), 815-17, 1577-85, 1610
adjunctive therapy, 842
catheter characteristics and materials, 1579-81, 1589
catheter management, 1583-4
children, 735, 742-3
frail elderly, 998
indwelling catheters compared with, 1584-5
meningomyelocele, 913

overall recommendations, 1610
research priorities, 1611
risk and complications, 816-17, 1581-3
infections, 817, 1577, 1581-2
in spinal cord injury, 903
and bacteriuria occurrence, 902
in SUI due to sphincteric incompetence, surgery for patients not using or not prepared to use, 842-5, 855-7
techniques and materials, 816

user characteristics, 1579
intravenous electrical stimulation (and neuromodulation), 24, 828-9

for patients with LUTS, 89
costs, 1708
different countries, 1689-90, 1708
estimated numbers of individuals with LUTS, 89
International Painful Bladder Foundation, 1683
International Prostate Symptom Score (IPSS), 351, 352, 386, 400

internet, education resources, 1658
interoceptive cortex, 230
interoceptive representation, forebrain, 231
interrater reliability, 366
interstitial cells of Cajal, 138, 139
interstitial cystitis see bladder pain syndrome

International Cystitis Association, 1682
International Cystitis Collaborative Research Network (ICCRN), 1745, 1746
Interoceptive Cystitis Database (ICDB), 1468, 1474, 1475, 1498
interstitial radiotherapy see brachytherapy

intervertebral disc disease/disorders, 801
lumbar, 911-12

intestine see bowel
intramural drugs in bladder pain syndrome, 1487
intraurethral (occluding) devices see occluding devices
intravaginal devices, 1572-5

pessaries, 1100-5, 1106, 1108, 1572-3
resistance devices, 1044
pelvic floor muscle training plus, 1045, 1046
rings, 1100-5, 1572-3, 1573
intravaginal sling procedure, 1219
intravenous urography/ pyelography, 548
intravesical drugs and chemicals (transvesical instillation/injections), 822-4
atropine, 822-3
BCG, in bladder pain syndrome, 1487
botulinum toxin A, 661-2, 663, 665

in bladder pain syndrome, 1488

men, 1146
chondroitin sulfate, in bladder pain syndrome, 1487
DMSO in bladder pain syndrome, 1486-7
heparin, in bladder pain syndrome, 1487
hyaluronic acid in bladder pain syndrome, 1487
lidocaine, in bladder pain syndrome, 1487
in neurogenic LUT dysfunction, 822-4
nociceptin/orphanin FQ, 822
oxybutinin, 655, 822

in bladder pain syndrome, 1488

children, 743
frail elderly, 992
pentosan sulfate, in bladder pain syndrome, 1487
phenol, 1238
propylène glycol, 822
vaniloids, 666-8, 823

in bladder pain syndrome, 1487-8
spinal cord injury, 903-4

intravesical potassium chloride challenge, 1475-6
intravesical pressure (bladder pressure)
difference between urethral pressure and see urethral closure pressure
with involuntary leakage of urine see leak point pressure
measuring, 419
urine flow rate and, relationship see pressure-flow studies see also filling cystometry

intrinsc sphincter deficiency see urethral sphincter

Intro to Responsible Conduct of Research (US Office of Research Integrity), 1756
Introl, 1573-4

invasive diagnostic procedures, enuresis, 710-12
investigations (sophisticated testing), 413-630
correlation with symptoms in females, 340-1
fistula evaluation, 1435

see also diagnostic tests
ion channels, 145-9
detrusor, 122, 144
as molecular targets, 652-3
novel agents, 144-9

see also specific ions
IOQ (Incontinence Outcome Questionnaire), 379
IPSS (International Prostate Symptom Score), 351, 352, 386, 400
I-QoL (Urinary Incontinence QoL Scale), 379, 382
irritable bowel syndrome, 232, 233, 234

postpartum, 299
irritative agents, bladder, animal studies, 223
ischaemic heart disease, 61
ischio cavernous muscle, innervation, 188

isotopic scans, upper urinary tract, 549

IBQ (Incontinence Screening Questionnaire), 385
Israel

family physicians, 1656
National Center for Continence, 1655, 1681
Italian version of Female Sexual Function Index, 398

Italy, continence organisations, 1681

in bladder pain syndrome, 1488

needs for services, 1653
joint disease, degenerative, frail elderly, 971

justice, 1756

Japan

Continence Action Society, 1650, 1665, 1681

kappa opioid receptor agonists, 181
Kegel’s exercises see pelvic floor muscle training
Kelly, Howard A, 28
Kerala, obstetric fistula prevention, 1437
KHQ (King’s Health Questionnaire), 380, 382
kidneys
  function
    intestinal reservoir effects on, 756-7
    paediatric neurogenic bladder and monitoring of, 744
    imaging, 546, 548, 549
  injury with obstructed labour, 1431
  stones see stones
transplantation in myelodysplasia, 459
Kock pouch
  child, 754
  complications, 757
Kontinensoreningen (Danish Continence Association), 1680
Korea Continence Foundation, 1681
Kropp procedure, 845

L-region (continence centre), pontine, 212, 220
laboratory examination
  bladder pain syndrome, 1475
  nocturnal enuresis, 720-1
labour
  epidural analgesia, 268-9
  obstructed (and consequent injury and fistula development), 1422, 1429-34
  prevention of fistulas, 1436
  second stage
    management affecting continence, 1668
    prolonged, FI risk, 1337
  see also childbirth
lactose, dietary, 1347
  intolerance (and lactase deficiency), 1347
  older people, 1366
lamina 1 afferents, 227, 228, 230, 231
language
  in questionnaires, 367
UI prevalence in women and, 47
laparoscopic surgery
  non-obstetric fistula, 1251
POP surgery, 1278
  colposuspension see colposuspension
  sacrocolpopexy, 1286
  ventral rectopexy, 1309
  radical prostatectomy, 1128
laser surgery/resection
  prostate, and UI risk, 1136
  urodynamic studies, 451
urethral sphincter, 837
latex catheters, 1589
laughter (giggle) incontinence, 732-3, 764
laundry facilities for continence devices, 1525, 1557
laxatives, 1352, 1375
  children with neurogenic detrusor-sphincter dysfunction, 743
  older people, 1371
  overuse, 1366
Le Fort colpocleisis, 1292
leaves/leaves, male (pouches), 1540, 1548, 1549
leak point pressure, 432-4
  abdominal, 419
  in coughing see coughing
  detrusor see detrusor leak point pressure
  men, preoperative, 1124-5
  reliability, 433-4
  severity of UI and, correlation studies, 443
  in SUI, influencing surgical outcome, 446, 1228
Valsalva, 274, 422, 432, 433, 443, 444, 446
leakage
  stools
    passive, 353
  products preventing or containing, 1612-18
  urine
    assessment with continence devices, 1533
    bladder pressure with involuntary leakage of see leak point pressure
    with pads, freedom from, 1552, 1556
learning disability/mental retardation, 800
FI risk, 1338
  nocturnal enuresis and, 42
  see also cognitive impairment
leaves/leafs, male (pouches), 1540, 1548, 1549
leg bags, 1561-2, 1562, 1564, 1565, 1566
Leicester Impact Scale (LIS), 380, 382, 1735
Leicester Urinary Symptom Questionnaire (LUSQ), 383, 385
length-tension relationship in LUT smooth muscle, 135
Leonardo da Vinci, 22
leucotomy and bladder control, 217
leukotriene antagonists, bladder pain syndrome, 1485-6
levator ani muscles, 582-3, 583-6
  female
    childbirth effects, 266, 267, 565-7, 586-8
    innervation, 184-8
    myorrhaphy, 1286
    pelvic organ prolapse and, 187-8
    racial differences, 588
    hiatus, size changes, imaging, 586
    innervation, 197
    female, 184-8
    MRI, 582-3
    defects/injury and bulk, 583-6
    plate angle change, imaging, 586
    ultrasound of trauma, 565-7, 571
  levator ani nerve, 184, 186
  continence in sneezing and, 194
levodopa, 887, 890
Lewy body dementia, 880-1
lidocaine, bladder pain syndrome, 1488
life expectancy, remaining, treatment of frail elderly and role of, 978
lifestyle, continence devices, 1525
  pads, 1557
lifestyle interventions
  FI, 1341-3, 1374
  frail elderly, 984
    recommendations, 1007-8
    men, 1083-4
    future research directions, 1094
    literature search strategies, 1108
    recommendations for practice, 1094
    women with POP, 1095-7
    literature search strategies, 1108
    recommendations for practice, 1106
    women with UI, 1028-34
    future research directions, 1081
    literature search strategies, 1107
    recommendations for practice, 1079
ligaments (pelvic region)
  sacrospinous see sacrospinous ligament suspension
  uterosacral, suspension, 1280, 1286
limbic behavioural motor cortex, spino-thalamic input to, 230
liners see inserts
linguistic validation, patient-reported outcome questionnaires, 367
lipomeningocoele, 458
LIS (Leicester Impact Scale), 380, 382, 1735
literature/publications, general points on continence devices (inc. expert opinion)
handheld urinals, 1534-5
sheaths, 1560-1
urine drainage bags, 1566
literature/publications review, transient UI in older people, 309
literature/publications searches
conservative treatment
POF, 1108-9
post-prostatectomy UI, 1082
UI in men, 1108
UI in women, 1107-8
continence awareness, 1646
continence products, 1521
drug therapy, 633
economic analysis, 1708
Fl, 1323-30
biofeedback and anal sphincter/pelvic floor training, 1353-4
bowel management and retraining programmes, 1348
diet and fluid intake, 1343
electrical stimulation, 1360
frail elderly, 1362
lifestyle interventions, 1341
neurogenic, 861-2
prevention, 1341
surgery, 1389-90
fistulas in developing world, 1421
frail elderly with UI, 964
neurogenic UI, 800
patient-reported outcome assessment, 363-4
neurogenic UI, 800
patient-reported outcome assessment, 363-4
primary prevention, 1666
professional education, 1658
SUI surgery in women, 1194
physical therapy, 917
recommendations, 1080
incontinence in men and women, 1086
research recommendations, 1007
surgical, 997
symptoms see symptoms
lower urinary tract dysfunction
assessment of urodynamic studies
children, 728-9
classification, 729-30
urodynamics, 465-7
men, urodynamic studies, 450-1, 454
neurogenic see neurogenic LUT dysfunction and incontinence
older people/elderly, outcome measures, 1740
lubricants for catheters
indwelling catheters, 1599, 1600
intermittent catheters, 817, 1580
men, 1579
lumbar spine
disc prolapse, 911-12
imaging, 605
lung disease see pulmonary disease
lupus erythematosus, systemic, 801, 920
LUSQ (Leicester Urinary Symptom Questionnaire), 383, 385
luteinising hormone-releasing hormone antagonists, 670-1
M
Macroplastique®
see polydimethylsiloxane
magnetic resonance imaging (MRI), 550, 578-97
brain (functional imaging), 605-7
bladder function studies, 217, 219
pelvic floor muscle studies, 583
dynamic see dynamic MRI
Fl, 612
methodology, 578-97
other imaging modalities compared with, 593-4
pelvic floor dysfunction, 578-97
SUI, 276
upper urinary tract, 548
urethral diverticula, 603
urethral diverticulum, 1245-6, 1246
magnetic stimulation
brain, 827
pelvic floor and sacral nerve roots, men, 1091-2, 1145
electrical stimulation compared with, 1089
future research directions, 1095
pelvic floor and sacral nerve roots, women, 1067-70
electrical stimulation compared with, 1065
future research directions, 1082
literature search strategies, 1107
recommendations for practice, 1080
Mainz II pouch, child, 747
Malaysia, Continence Foundation, 1681
male(s), 299-308, 1121-90
alloplastic sphincter, 29-30
bladder outlet endoscopy, 609
bladder pain syndrome in digital rectal examination, 1475
care-seeking behaviour, 1647
causes of risk factors for UI, 65-70, 302-7
prostatectomy see prostatectomy
conservative treatment of UI, 1082-95, 1108
continence devices
bags, 1529
bodyworn urinals, 1529
dribble containers, 1528
handheld urinals, 1526, 1534
indwelling catheters, 1529
mechanical devices see mechanical continence devices
pads for moderate/heavy UI, 1529
pads/absorbent products for light UI, 1528, 1546-8
pads/absorbent products for moderate/heavy UI, 1546-8
recommendations, 1552
sheaths see condom catheters
continence mechanisms, 300-2
epidemiology of UI, 64-72, 349-50
frail older, management of UI recommendations, 1007
surgical, 997
indwelling catheters, lubrication, 1579
initial assessment of UI, 349-51
LUTS see symptoms
pathophysiology of UI, 299-308
pelvic trauma, 1141-2, 1169
physical examination, 351-2
digital rectal examination, 347, 351-2
post-void residual urine, determination, 339-40
sexual dysfunction
penile erection see erectile dysfunction
questionnaires in assessment of, 395, 396, 398-9
SUI see stress incontinence
surgery see surgery
urethral occlusion devices, external (compressive), 1575-6
historical accounts, 22, 24, 29-30
with sling, 1129-31
urethral occlusion devices, internal, adjustable balloons, 1131-3
urodynamic studies, 450-5
UUI see urge UI
see also boys; gender
Male Urinary Symptom Impact Questionnaire, 380
Male Urogenital Distress Inventory (MUDI), 380
Male Urinary Symptom Impact Questionnaire, 380
urinary incontinence, see also boys; gender
maximal volume voided, measurement, 336
maximum urethral closure pressure
maximum cystometric capacity, child, 712
matrix metalloproteinases (MMPs), 627, 628
maternal factors
mast cells in bladder pain syndrome, 1473
mass, body
marsupialisation, open and transurethral, 1247
Markov model, 1693-4
Marshall-Marchetti-Krantz (MMK) procedure, 1198-202
marsupialisation, open and transurethral, 1247
Martius flaps/grafts, 1440, 1445, 1446
mass, body see body mass
massage see abdominal massage
mass cells in bladder pain syndrome, 1473
activation, 222, 1469, 1473
counting, 1477-8
maternal factors
FL, 1337
POP, 282-3
matrix metalloproteinases (MMPs), 627, 628
maximum cystometric capacity, child, 712
maximum urethral closure pressure see urethral closure pressure
maximum volume voided, measurement, 336
Mayo culdoplasty, 1286
mechanical continence devices, 1567-76
females, 1567-75
light UI, 1527
males, 1575-6
historical accounts, 22, 24, 29-30
intra-urethral, 1131-3
light UI, 1528
moderate/heavy UI, 1529
mechanical failure of artificial urinary sphincter, 1164
treatment, 1168
mechanical stimulation
bowel evacuation triggered by, 867, 867-8
sacral reflexes, on, 536
urothelial role in sensing, 173-5
mechanical trauma see injury
mechanics/biomechanics
bladder wall, 132-7
pelvic floor muscles
MRI assessment, 588
ultrasound assessment, 565
media in continence promotion, 1649-50
medial prefrontal cortex, 221
medial reticular formation, 211
medical conditions, comorbid/pre-existing see comorbid and pre-
existing
Medical, Epidemiological and Social Aspects of Aging (MESA)
questionnaire, 385
medical education on incontinence, 1658-9
medical history
in FI aetiology, 354
taking see history-taking
medical management see conservative/medical management
medication see drug
Medizinische Gesellschaft fur Inkontinenzleben Österreich, 1680
medullary cone see conus lesions
megacolon, congenital (Hirschsprung’s disease), 138
membrane, ion channels, see specific ions
Memokath™, 836
men see males
meningomyelocele see myelomeningocele
menopausal/postmenopausal women, risk of UI, 60
HRT and, 57-8
menstrual pads, 1544, 1545, 1546, 1547
mental disorders see psychiatric and psychological disorders
mental retardation see learning disability
meperidine (pethidine), chronic pelvic pain, 1491
Mersiline® sling, 1215
MESA (Medical, Epidemiological and Social Aspects of Aging)
questionnaire, 385
mesencephalon (midbrain) and bladder function, 202-14
meshes, synthetic
anterior wall prolapse, 1300-1
sacrococcygeal, 1279
ultrasound aiding implantation, 571
metabolism, intestinal reservoir-related disturbances, children, 755-6
metabotropic receptors, 140-4
metallloproteinases, matrix (MMPs), 627, 628
methadone, chronic pelvic pain, 1491
methamine hippurate and indwelling catheters, 1595
methotrexate, bladder pain syndrome, 1485
methoxamine, 763
N-methyl-D-aspartate see NMDA
Mexico, continence organisation, 1681
microglia, spinal cord, 183
micturition, 209-13
central pathways controlling, 207, 209-11, 212-13, 214-17, 220, 231, 634
control, development, 703-4
dribbling after see dribble
frequency of see frequency
inappropriate see urinary incontinence
off-switching, 212
on-switching, 209-11
see also post-micturition; voiding
micturition reflex (bladder reflex; voiding reflex), 182-3
circuity/paths, 212-15
supraspinal see supraspinal pathways
in non-neurogenic detrusor overactivity, changes, 260
ORL receptors and, 180, 181
suppression, 212-13
triggering (triggered reflex voiding), 811, 813
micturition time chart, see also frequency/volume chart
midbrain and bladder function, 202-14
midline fascial plication, 1290
midodrine, 672, 763
mid-urethral tapes see tension-free vaginal tape
Miniguard, 1569
minimal important difference of measure, 366-7
Minimally Clinically Important Change (MCID), women after UI
surgery, 1254
minimally invasive surgery of non-obstetric fistulas, 1249
see also endoscopic surgery; laparoscopic surgery
misoprostol, bladder pain syndrome, 1486
Mitrofanoff procedure, child, 753-4
mixed (urge and stress) UI
muscarinic (M) receptors (for ACh), 118, 120, 123, 128, 140, 149, 151, 157
multivariate regression analysis, 1694
motor unit, 526
multidisciplinary care, 1653
multi-attribute utility instruments, 1695-6
MUDI (Male Urogenital Distress Inventory), 380
mucus from intestinal reservoirs
mucosa
moxifloxacin, 649-50
motor neurones/innervation (efferents)
motor evoked potentials, 533, 537-8
motor cortex, limbic behavioural, spino-thalamic input to, 230
motor evoked potentials (MUPs) in concentric needle EMG, 527-9
motor system, somatic see somatic motor system
motor potentials (MUPs) in concentric needle EMG, 527-9
mucosa
anorectal, sensitivity testing, 489-91
bladder, 198-207
inhibitory, 205
lesions, lower see conus lesions
levator ani
cholera toxin-B labelling, 197
females, 186-7
urethral rhabdosphincter, 188-9
neurochemical anatomy, 194
motor system, somatic see somatic motor system
myo-rectal, 497, 527, 529, 532
myosin light chain phosphatase (MLCP), 121, 122
myosin light chain kinase (MLCK), 121
myosin, in detrusor contraction, 121
myocardial infarction
myofascial release treatment, bladder pain syndrome, 1480-1
myogenic basis/hypothesis of spontaneous detrusor activity, 124, 262
myopathies, EMG, 531-2
myorrhaphy, levator, 1286
myosin, in detrusor contraction, 121
myosin light chain kinase (MLCK), 121
myosin light chain phosphatase (MLCP), 121, 122
myotomy, bladder see autoaugmentation

N

NAFC (National Association For Continence), 1646, 1647, 1650, 1658, 1682
National Association For Continence (NAFC), 1646, 1647, 1650, 1658, 1682
National Center for Continence (Israel), 1655, 1681
National Continence Management Strategy (NCMS), Australia, 1648-9
National Family Health Survey (India) and obstetric fistulas, 1437
National Health and Nutrition Examination Survey (NHANES) in US, FI prevalence estimates, 1330
National Institute of Diabetes, Digestive and Kidney Disorders/NIDDK (on bladder pain syndrome), 1462, 1464
classification, 1480
definitions, 1462, 1464
diagnosis/assessment, 1475, 1475-6
drug therapy, 1483, 1484
National Institute for Health and Clinical Excellence (NICE)
pharmacotherapy of overactive bladder, 1702
sacral nerve stimulation, 1244-5
on surgical interventions, 1752
new procedures, 1754
National Institutes of Health (NIH), research on incontinence in children, 1741, 1742
National Men’s Continence Awareness Project (Australia), 1649
national organisations, 1657, 1658, 1680-3
National Overactive Bladder Evaluation (NOBLE), 349
National Pressure Ulcer Advisory Panel (NPUAP), 1620
natural history of UI in frail older and disabled people, research, 1739
NCMS (National Continence Management Strategy), Australia, 1648-9
Nd/YAG laser sphincterotomy, 837
NEAT device, 1571
needle EMG, 527-9
external anal sphincter, 497, 527, 529, 532
needle suspension (bladder neck), 1202-3
nerve growth factor (NGF), 181
neural tube closure defects (myelodysplasia), 457-9, 740, 741
Netherlands (Holland)
nervous system, 167-253, 634-6, 797
nerve supply (innervation) to pelvic floor in FI pathogenesis, 289
nerve injury/lesions, peripheral (incl. denervation of pelvic floor), 132
nerve supply (innervation) to LUT, 634-6
nerve roots, sacral see sacral nerve roots
nerve supply (innervation) to LUT, 634-6
anorectum, 157-18, 138-9, 286
bladder/bladder wall
bladder base and trigone, 126
detrusor contraction and, 123-4
denervation (technique) see denervation (technique)
lesions see nerve injury
levator ani see levator ani
urethra, 127
urethral sphincter see urethral sphincter
nerve supply (innervation) to pelvic floor in FI pathogenesis, 289
nervous system, 167-253, 634-6, 797
autonomic see autonomic nervous system; parasympathetic nervous system; sympathetic nervous system; central see central nervous system
enteric see enteric nervous system
regulation by, 167-253, 634-6
see also nerve supply and entries under neuro-Netherlands (Holland)
continence organisations, 1681
costs, 1690
networking, continence organisations, 1658
neural pathways and control see autonomic nervous system; central nervous system; enteric nervous system; nerve supply; nervous system; parasympathetic nervous system; sympathetic nervous system; myelodysplasia, 457-9, 740, 741
neuroactive agents, lower urinary tract, 128-32, 912-16
Neurobloc® (botulinum toxin B), 666
neurogenic bladder see neurogenic LUT dysfunction
neurogenic detrusor overactivity, 258-9
children
botulinum toxin A, 664, 739
urodynamic studies, 456
drug therapy, 643-5, 820, 821-2
toxins, 661-8
pathophysiology, 258-9
urodynamic studies, 456
children, 457-62
distinguishing and defining characteristics, 438-9
neurogenic detrusor-sphincter dysfunction, children, 740-4
neurogenic FI (neuropathic FI), 861-77
aetiology, 861-3, 877-922, 1338-9, 1365-6
conservative management, 867-70
surgery following failure of, 870
epidemiology, 78, 861-3
management
conservative see subheading above
in specific neurological diseases, 878-922
surgical, 870-7
special diagnosis, 864-6
neurogenic hypotheses
bladder pain syndrome aetiology, 1470-1
spontaneous detrusor activity, 124
neurogenic inflammation and bladder pain syndrome, 222
neurogenic LUT dysfunction and incontinence (incl. neurogenic bladder), 455-7, 799-861
children, classification, 713
classification, 1702-3
diagnostics and investigations, 802-11, 1743
imaging, 552
urodynamic studies see urodynamic studies
epidemiology and aetiology, 69, 799-802, 877-922
management, 1741
conservative, 811-29
surgery see surgery
research see research
neurogenic sphincter dysfunction or deficiency, drug therapy, 820, 824-5
neurography, sensory, 534
neuroimaging, 605-7
bladder control studies, 216-20
functional see functional brain imaging
visceral stimuli, 231-3
neurokinins (NKs)
noradrenergic A, 132, 179-80
receptors (and agonists/antagonists), 132, 179-80
NK-1 antagonists, 671-2
NK-1, 132
NK-1 antagonists, 671-2
NK-2, 132, 179-80
NK-3, 179-80
neurological disorders/diseases, 793-960
AI/FI due to see neurogenic FI
bowel in see bowel
comorbid, frail elderly with UI, 970-2
minor, children, associated with day wetting, 45
UI due to see neurogenic LUT dysfunction and incontinence
see also central nervous system; nerve supply and entries under neurogenic
neurological examination, female IU, 342
neurological injury see nerve injury
neuromodulation, electrical see electrical stimulation
neuromodulators in brainstem controlling bladder function, 213-14
neurogenic
afferent/sensory see sensory nerves/neurones
continence centre, in brain, 211
efferent/motor see motor neurones
'tilling', in brain, 211
neurophysiological studies and tests (incl. electrophysiology), 523-40, 808-11
biological correlates, 525-7
classification of tests, 525
evidence-based use, 537-8
in Fl, 496-8
neuropathic patients Non-continent cutaneous diversion, 865-6
methodological considerations, 526-7
in neurogenic LUT dysfunction, 808-11
spinal cord injury, 899-900
recommendations, 538-9
in research, usefulness, 538
tests used, see also specific tests
urethral function, 275
urethral sphincter see urethral sphincter
neurophysiology
clinical see neurophysiological studies
research in see research
neuropathic dysraphism see spinal dysraphism
neurotoxin see botulinum toxin A
neurotransmitters, 128-31
bladder, 200-2
in brainstem controlling bladder function, 213-14
urethral and anal rhabdosphincters and, 194-5
neurotrophins, 181-2
see also specific types
neuromonology, 803
New Zealand
Continence Association, 1681
family doctor services, 1656
newborns see infants
NGF see nerve growth factor
NHANES (US), Fl prevalence estimates, 1330
NICE see National Institute for Health and Clinical Excellence
nicotine (from smoking), 1031
nicotinic receptors, 131, 198
NIDDK see National Institute of Diabetes, Digestive and Kidney Disorders
nifedipine in bladder pain syndrome, 1486
night drainage bags, 1561, 1562, 1563, 1564, 1565
see also entries under nocturnal
NIH, research on incontinence in children, 1741, 1742
nitric (NOS-containing) mechanisms, 131
nitric oxide (NO), 126, 131, 179, 659
bladder base and trigone and, 126
bladder pain syndrome pathogenesis, 1471
urethral smooth muscle relaxation, 127
nitric oxide synthase, 131
NKs see neurokinins
NMDA (N-methyl-D-aspartate) receptors, 183
antagonists, in chronic pelvic pain, 1492
cerebrovascular accidents and LUT problems and, 891-2
urethral and anal rhabdosphincters and, 194
N-methyl-D-aspartate see NMDA
NO see nitric oxide
NOBLE (National Overactive Bladder Evaluation), 349
nociceptin/orphanin FQ, 180-1
in neurogenic LUT dysfunction, 822
nociception see pain
NOCTOPUS programme, 680
nociception (waking to void), 335, 1747-8
bladder training, 1078
definition, 335
drug therapy see drug therapy
frail elderly, 999-1001
recommended management, 1009
pathophysiology see pathophysiology research, 1747-8
see also nocturnal diuresis; nocturnal frequency
Nocturia Quality of Life Questionnaire, 380
nocturnal detrusor overactivity, children, 717
nocturnal diuresis, older people, 311
see also nocturia; nocturnal frequency
nocturnal enuresis (bedwetting), 38-42, 466-7, 714-26, 761, 762-3, 769, 770
adult males, 454, 456
classification, 715-16
primary vs secondary, 715
definitions and terminology, 38-9, 714
diurnal and see daytime and night-time wetting
epidemiology incl. prevalence, 39-41, 714, 761
behavioural disorders, 762-3
gender and, 41, 715
management/therapy, 718-26, 763
evidence-based recommendations, 721-6
non-responders, 725
pharmacological see drug therapy
urotherapy, 769, 770
monosymptomatic (MNE), 38, 41, 714, 715, 715-16
pathophysiology, 716-18
non-monosymptomatic (NMNE), 38, 43-5, 715
risk factors, 41-2
severity, 714
urodynamic studies, 466-7
nocturnal frequency (frequency of night-time micturition), measurement, 336
nocturnal frequency, older people, drug therapy, see also nocturia;
nocturnal diuresis
nocturnal polyuria
children, 716-17
measurement, 336
multiple system atrophy, 884
NOFUS (Norwegian Society for Patients with Urologic Diseases), 1681
non-blinded (unblinded) trials, 1716, 1722
non-compliance see compliance
non-continent (conduit) urinary diversion, neurogenic LUT dysfunction, 858-61
non-inferiority trials, 1717-18
non-neurogenic detrusor overactivity, 259-64
non-neurogenic LUT dysfunction in children, 730
non-parametric studies, 1725
non-randomised controlled trials, 1716
non-steroidal anti-inflammatory drugs (COX inhibitors;
prostaglandin synthase inhibitors; NSAIDs)
chronic pelvic pain, 1490
nocturnal enuresis, 723
overactive bladder symptoms/detrusor overactivity, 660-1
noradrenaline see norepinephrine
norephedrine (phenylpropanolamine; PPA), SUI, 672, 673
norepinephrine (noradrenaline), urethral and anal rhabdosphincters, 194
norepinephrine and serotonin reuptake inhibitors see serotonin and
norepinephrine reuptake inhibitors
normalised micturition frequency, measuring, 336
Norwegian Society for Patients with Urologic Diseases (NOFUS), 1681
NPUAP (National Pressure Ulcer Advisory Panel), 1620
N-Qol, 380
NTM (Inco) Forum, Poland, 1681
nucleus tractus solitarius (NTS), 210, 227, 228, 230, 231
nurse(s), 1652-3, 1661-3, 1704-6
advanced practice see advanced practice nurses
as continence advisors see continence nurse advisors
education/training, 1661-3
specialist, 1654-5, 1661-2, 1663
nurse practitioners, continence, 1652-3, 1663
Nurses Health Study, 678
physical activity in, 1030
nursing assistants and aides, 1664
nursing home (and other long-term care institutions for elderly), 1004-5
absorbent bodyworn products in, evaluation, 1550, 1551
AI/FI in, 78, 1362
management, 1370-1
residency as risk factor, 1331
caregivers in, training, 1664
costs of care, 1704-6
staff in, interventions with, 988-9, 1009
UI as risk factor for admission, 964-5
UI in women in, 51, 61-2
nutrient supply for tissue-engineered grafts, 150-1
nutritional factors see dietary factors

O

OAB-Q (Overactive Bladder Questionnaire), 381, 382
OAB-S (Overactive Bladder Treatment Satisfaction Questionnaire), 383, 384
OAB-SS (Overactive Bladder Symptom Score), 385, 387
OAB-V8/OAB Awareness Tool, 383-4, 385
obesity and overweight, 1667
female, 1028-9
as risk factor for POP, 283
as risk factor for UI (in general), 57, 64, 1028-9, 1667
SUI surgical outcome and, 1223-4, 1232
FI and, 74-6, 1331
see also weight
OBJECT trial, 646
observation(s), in research, ICS Standardization Committee recom-
mendations, 1730-1
observation techniques in cognitive-behavioural therapy, 769
surgery, 1751
observational studies, 1717
obstetrics see childbirth; pregnancy
obstruction (LUT), bladder see benign prostatic hyperplasia/enlarge-
ment/obstruction; bladder obstruction; bladder outlet
obstruction; urethral strictures
occluding devices, 1567-72
extra-urethral
females, 1567-70
males see males
intra-urethral
female, 1570-2
males, 1131-3
occupational risk factors, 1668
FI, 1341
women, POP, 85, 1096
interventions related to, 1096
see also physical exercise
O’Connor repair, 1447
odds ratio, definition, 38
odour control products, 1626-8
oestrogens, 676-8
continence mechanisms and, 676
deficiency, and overactive bladder, 261
POP risk associated with, 283
therapeutic use in incontinence, 676-8
frail elderly, 992, 994-5
tissue analysis, 628
UI aetiology, 57-8, 64
urethral smooth muscle relaxation and, 127
see also hormone replacement therapy; selective oestrogen
receptor modulators
office evaluation
economic aspects, 1687, 1707
pad testing, 618-20
Office of Research Integrity (US), Introduction to Responsible
Conduct of Research, 1756
older people/elderly, 961-1024, 1362-73
Al/FI in, 1362-73, 1376
antimuscarinics see antimuscarinics
bladder, 965-8
dysfunction, 260-1
conservative treatment, 984-95
drugs see drug therapy
continence services, 1656
frail see frail elderly
LUT dysfunction, outcome measures, 1740
nocturia see nocturia
nursing homes see nursing home
patient-reported outcome assessment, 400
physiological/pathological changes, detrusor overactivity, 261
prevention of UI, 987, 1669-70
research see research
surgery see surgery
transient incontinence, causes, 308-11
see also age
O’Leary-Sant (OLS) questionnaire, 1467-8, 1475, 1495, 1496, 1498
OLS (O’Leary-Sant) questionnaire, 1467-8, 1475, 1495, 1496, 1498
omentoplasty in non-obstetric fistula repair, 1251
one-hour pad test, 619-20
Onuf’s nucleus, 187, 194, 636
OPERA trial, 646, 654
operant behavioural strategies, 986
operating theatre time, fistula in developing world, 1450-1
opioid (opiate) receptor(s), agonists, 181
opioid receptor-like 1 receptor, 180-1
opioid(s) (opioid receptor agonists), 181
bladder pain syndrome, 1482
chronic pelvic pain, 1490-1
opioid receptor-like 1 receptor, 180-1
OPTIMAL trial, 1754
OPUS trial, 1754
organisations, continence, 1657-8
directory of, 1680
networking, 1658
ORL1 receptor, 180-1
orphanin FQ see nociceptin
Orr-Loygue rectopexy, 1309
orthopaedic trauma in obstructed labour, 1433-4
orthotopic neobladder see neobladder
outcome(s)
of catheterisation (intermittent vs indwelling), 1584
of conservative interventions for female UI, factors affecting
electrical stimulation, 1066-7
lifestyle modification, 1034
magnetic stimulation, 1070
pelvic floor muscle training, 1054-5
scheduled voiding incl. bladder training, 1078-9
vaginal cones, 1058
of conservative interventions for male UI, factors affecting
electrical stimulation, 1091
magnetic stimulation, 1092
pelvic floor muscle training, 1087
scheduled voiding, 1092-3
continence devices
external devices, 1532-3
internal devices (catheters), 1592-3
in economic analysis, 1695-6
in cost-utility analysis, 1696
in FI intervention
  resting anal pressure and prediction of, 479-80
  sacral nerve stimulation, 1402
  voluntary squeeze pressure, 484
in frail elderly
  measures, 1740
  treated for UI, defining, 978
functional, enterocystoplasty, 853
measurement, 1729-36
LUTS, 1729-36
MRI assessment of treatment outcome, 592-3
  patient-reported see patient-reported outcome assessment
  surgery for SUI in women see subheading below
in trials, 1721, 1727
of POP surgery
  anatomical aspects, 1276
  MRI, 592
  primary, 1721, 1727
  research see research
  secondary, 1721, 1727
of SUI surgery, measurement, 1252-5
  confounding variables affecting, 1220-8
urodynamic studies in geriatric patients and effects on, 472
outpatient conservative management, economic analysis, 1700-2
overactive bladder (OAB; bladder overactivity; urge syndrome; urgency ± UI) and OAB syndrome, 258-64, 639-72, 677-8, 1702-4
children, 730-1
  prevalence, 43
  therapy, 731, 735
  definition, 334
  drug therapy, 630-72, 1702-4
  continent awareness and promotion, 1702-4
  hormonal, 677-8
  trials aiding economic evaluation, 1705
economic burden of disease, 1706
epidemiology, 72, 349
  worldwide estimates of numbers of individuals, 89
  filling cystometry in diagnosis of, 434-40
  pathophysiology and pathogenesis, 258-64, 636
  patient-reported outcome questionnaires, 377-403
  screening tools, 383-8
  urodynamic studies in, 436-8
  with coexisting SUI, 436
  see also detrusor overactivity; National Overactive Bladder Evaluation
overactive pelvic floor, children, treatment, 739
overactive urethral sphincters, children
  detrusor overactivity with, 742
  detrusor underactivity with, 742
surgery, 745
overdistension, bladder see cystodistension
overflow FI (FI due to constipation and stool impaction)
  drug therapy, 676, 1351-2, 1371, 1375
  older people, 1351, 1364-5, 1370-1
  prevalence, 1365
  treatment, 1351, 1370-1
  see also faeces, impaction
overflow UI, urodynamic studies, 456
overlearning, 771
overweight see obesity and overweight
Oxford Guidelines (levels of evidence)
  clinical drug recommendations, 633
  research recommendations, 1716
oxybutin, 653-5, 992-3, 1704
  bladder/detrusor overactivity, 646-7, 653-5, 656, 821, 822
  children, 738, 738-9
  bladder pain syndrome, 1488
  economic analysis, 1702, 1704
  extended-release see extended-release formulations
frail elderly, 990-3
neurogenic detrusor-sphincter dysfunction, children, 743
neurogenic UI, 821
intravesical, 822
  in spinal cord injury, 903
  nocturnal enuresis, 722
women, pelvic floor muscle training vs, 1051
oxyphencyclimine, 821-2

P

pad(s), absorbent
  containment with see absorbent products
testing with (pad weighting), 347, 618-25, 1733, 1734
  definition, 618
  home-based, 620-2
  indications and methodology, 618
  office-based, 618-20
  postoperative after UI surgery in women, 1253
  see also bedpads
paediatrics see children
pain
  in bladder pain syndrome
    assessment, 1475, 1489-90
    mapping, 1475
    see also bladder pain syndrome
catheter-related, 1608
  indwelling, 1600
pelvic see pelvic pain
sensation/nociception
  spinal glia and, 183
tachykinins and, 183
treatment
  chronic pelvic pain, 1490-2
  pharmacological see analgesia; drug therapy
PAIS (Psychosocial Adjustment to Illness Scale), 398
pants, washable absorbent
  evaluation, 1550, 1551, 1552
  men, 1546, 1548
  women, 1545, 1546
paracetamol, chronic pelvic pain, 1490
parallel trials, 1717
parametric studies, 1725
parasacrococcygeal transspincteric incision, rectourethral fistula repair, 1156
parasympathetic nervous system, 797
anorectum, 137
denervation in bladder pain syndrome, 1493
LUT, 634
  bladder, 198
  bladder neck and base, 126
  urethra, 127
  see also autonomic nervous system
paravaginal defect repair, 1203, 1288, 1288-90
Paré, Ambroise, 22
parents, impact of UI/enuresis on, 766-7
parity
  and FI risk, 1334
  and UI risk, 55
Parkinson’s disease, 863, 881, 886-90
detrusor overactivity, 258
FI, 863, 888-90
  multiple system atrophy and, differential diagnosis, 884
  UI and LUT dysfunction (in general) in, 454, 800, 881, 884, 886-8
  combined urodynamics and imaging, 552
  frail elderly, 971, 972
  urodynamic studies, 454-5, 472-3
Parrish, Joseph, 1462
parturition see childbirth
pathogenesis see aetiology
pathophysiology, 257-330
of FI, 799
older adults, 1363-4
of nocturia, 263-4
in the frail elderly, 999
of POP, 278-84
of UI see urinary incontinence
see also aetiology
patient(s)
adherence see adherence
assessment see assessment
FI risk factors related to, 1330-3, 1339
frail elderly, preferences for UI care, 979
history see history-taking
obstetric fistula risk factors (and prevention) related to, 1435
satisfaction with treatment see treatment
SUI surgery risk factors related to, 1231-2
in trials/research
informed consent see informed consent
observations, ICS Standardization Committee recommendations, 1730-1
Patient Global Impression of Severity and of Improvement (PGI-I and PGI-S), 388
Patient Perception of Bladder Condition (PPBC), 387, 388
patient-reported outcome (PRO) assessment, 363-412
for clinical trials and practice, 401-2
literature search strategy, 363
questionnaires see questionnaires
research recommendations, 403-4
types of PRO measures, 402-3
Patient Satisfaction Questionnaire (PSQ), 384
Pawlik, Karl, 27
PD-1151T, bladder pain syndrome, 1484
pelvic floor, 135
age-related changes, women, 968-9
anatomy, 184
obstetric, training of health professionals, 298-9
chronic stress, 283
electrical stimulation, 828
electromyography see electromyography
imaging in neurogenic FI, 865
innervation, in FI pathogenesis, 289
magnetic stimulation see magnetic stimulation
obstetrics and see childbirth; pregnancy
in POP, associated conditions, 284-5
properties, 135
relaxation, MRI grading, 590-2
research recommendations, 197
surgery, ultrasound, 571
trauma
in men, incontinence after, 1141-2, 1169
in women, due to childbirth, 266-8
Pelvic Floor Distress Inventory (PFDI), 391-2, 1746
intravaginal rings and pessaries and, 1103
pelvic floor dysfunction/disorders
birth injury, 266-8
children, treatment, 739
detrusor overactivity, 261
FI relating to, 354
imaging see imaging
symptoms of, 341
Pelvic Floor Dysfunction Network (PFDN), 1754
Pelvic Floor Impact Questionnaire (PFIQ), 391-2, 1746
intravaginal rings and pessaries and, 1103
pelvic floor muscle (and pelvic organ-supporting tissues)
deinnervation see nerve injury
electrical stimulation see electrical stimulation
EMG see electromyography
MRI, 579-82
neural control in females, 184-8
remodelling, in POP aetiology, 282
strength evaluation, 348
strength-increasing programmes, 1353
women, 1035-6
supraspinal activation, 193-4
tissue analysis, 627-9
ultrasound, 564-5
weakness and fatigue, definition, 348
pelvic floor muscle training/rehabilitation (PFMT; pelvic floor exercises), 1034-55, 1079-80, 1353-9
adherence (compliance), 1044-5, 1045-6, 1047, 1651
costs, 1689
in FI management, 1353-9, 1375-6
frail elderly, 985
men (incl. post-prostatectomy), 1083-6
combined with other treatments, 1085-7, 1090-1
compared with electrical stimulation, 1089
future research directions, 1095
literature search strategies, 1107
recommendations for practice, 1094
MRI assessment of outcome, 593
women, 1034-55, 1076, 1079-80, 1097-100
combined with other treatments, 1044-8, 1052-4, 1058, 1065-6, 1076
compared with other treatments, 1048-52, 1057, 1058
evidence for, 1036
future research directions, 1081
literature search strategies, 1107
pregnancy and postnatal period, 1036-42, 1079-80, 1668-9
preventive use, 1037, 1668-9
recommendations for practice, 1079-80
women with POP, 1097-100
future research directions, 1106
recommendations for practice, 1106
Pelvic Floor Netherlands, 1681
Pelvic Floor Patients Foundation, 1681
pelvic nerve afferents, electrical stimulation, 192-3
pelvic organ(s) (and tissues/viscera)
anatomical/structural aspects, 184, 278, 279, 1278-9
MRI, 579-82
supporting structures, 278, 279, 579-82
bimanual examination in bladder pain syndrome, 1475
interactions at efferent neural levels, 203-5
quantifying support, 1731
sensation
brain circuits activated by, 231-3
urothelial cell role in, 171-5
see also specific organs
pelvic organ prolapse (POP), 80-6, 278-85, 344-7, 579-88, 589-92, 1095-7, 1273-320, 1706-7, 1737-8, 1746-7
aetiology/risk factors, 82-5, 274-84, 1096-7
conservative, 1095-107, 1108
anatomical aspects of surgical outcome, 1276
comorbid conditions, 85, 284-5
FI, 1333
UI see subheading below
definitions, 80, 1746, 1747
epidemiology, 80-6
research recommendations, 93-4
help-seeking behaviour, 88
imaging, 579-88
in grading of relaxation, 590-2
MRI, 579-88, 589-92, 593
quantitative assessment, 567-70
ultrasound, 567-70
management, 1095-107, 1273-320
surgical see surgery
pathophysiology, 278-84
physical examination, 344-7
prevention see prevention
questionnaires assessing symptoms and health-related QoL
impact, 389-93, 397, 1746
research see research
symptoms see symptoms
UI and urinary tract dysfunction comorbid with, 347, 1228-9
surgical considerations, 1228-9
see also specific organs/tissues
Pelvic Organ Prolapse Distress Inventory (POP-DI) and intravaginal
rings and pessaries, 1103
Pelvic Organ Prolapse - Quantification (POP-Q), 344-5, 1731,
1746, 1747
ICS, 344
modified, 344
Q-tip test and, 343-4
simplified, 344
Pelvic Organ Prolapse Quantification Index (POP-Q-I), 345
Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire,
397
pelvic pain, chronic
case concept diagram, 1466
management, 1490-2
Pelvic Pain and Urgency/Frequency (PUF) questionnaire, 385, 1467,
1468, 1495, 1498
pelvic radiation see radiation
pelvic surgery (in general)
nerve damage due to, 802, 918
Parkinson’s disease patients, 888
previous history of, pelvic organ (incl. vaginal) prolapse risk
with, 82-3, 283
pelvic viscera see pelvic organs
pelvis, bony
MRI studies of racial differences, 588-9
POP risk related to, 283
trauma in obstructed labour, 1433-4
penile nerve, dorsal, electrical stimulation, 535
penis
compression devices see males
cuff device for pressure-volume measurements, 420-1
erective dysfunction see erectile dysfunction
sheaths see condom catheters
tissue engineering, 150
pentosan polysulfate, sodium (PPS), in bladder pain syndrome,
1484-5
intravesical/intramural, 1487
peranal surgical approaches see transanal approach
perception, conscious, of input from body as aspects of homeostasis,
230-1
percutaneous procedures
electrical stimulation, children, 735
sacral root block, 839-40
perianal examination in FI, 354
perineal approach
artificial urinary sphincter implantation, 1161
prostatectomy, 1128
rectal prolapse surgery, 1307-8
rectourethral fistula repair, 1156, 1157
SUI surgery, historical accounts, 28-9
perineal fistula, surgery, 1406-7
perineal pad testing see pads, testing with
perineometers, 348
perineum
cleansing/wiping from front to back (women), 1622
compression (of bulb urethra), historical account, 22, 24
dermatitis (=incontinence-associated dermatitis), 1618-26
descent, correlation with anal mucosal sensitivity, 490
examination, females with UI, 342
surgical incision see episiotomy
trauma in childbirth, 270-1
repair, training, 298-9
ultrasound for mesh implantation, 571
peripenile strap, 1575
peripheral excitatory mechanisms, 205-7
peripheral nerves see nerve supply; neuropathy
peripherally active drugs in overactive bladder/detrusor overactivity,
670
Periosteen Anal Irrigation system, 869
perirectal adjustable balloons, 1131-3
perirectal bulking agents see bulking agents
Permacol®,
anal canal injections, 1217, 1405
sling made from, 1216
per-protocol approaches to data analysis, 1724-5
personal hygiene, indwelling catheters, 1601
personal preferences and priorities for continence devices, 1525,
1557
personnalisation of products, 1557
pessaries, 1100-5, 1106, 1108, 1572-3, 1670
PET see positron emission tomography
pethidine, chronic pelvic pain, 1491
Peyronie’s disease, 150
PFDI see Pelvic Floor Distress Inventory
PFDN (Pelvic Floor Dysfunction Network), 1754
PFIQ see Pelvic Floor Impact Questionnaire
PGI-I and PGI-S (Patient Global Impression of Severity and of
Improvement), 388
pharmacists, 1663
pharmacology
age-related changes, 981-3
antimuscarincs, 641
urethral and anal rhodosphincters, 194-7
see also drug history; drug therapy
Pharmacy Continence Care Project (Australia), 1649
phase I-IV trials, 1718
phenol injection, transvesical, 1238
phenylephrine, FI, 1351
Phenylpropanolamine (PPA; norephedrine), SUI, 672, 673
Philippines, Continence Foundation, 1681
phosphodiesterase, 131, 658-9
phospholipase C, 128-9
pharmacists, 1663
personalisation of products, 1557
pessaries, 1100-5, 1106, 1108, 1572-3, 1670
PET see positron emission tomography
pethidine, chronic pelvic pain, 1491
Peyronie’s disease, 150
PFDI see Pelvic Floor Distress Inventory
PFDN (Pelvic Floor Dysfunction Network), 1754
PFIQ see Pelvic Floor Impact Questionnaire
PGI-I and PGI-S (Patient Global Impression of Severity and of
Improvement), 388
pharmacists, 1663
pharmacology
age-related changes, 981-3
antimuscarincs, 641
urethral and anal rhodosphincters, 194-7
see also drug history; drug therapy
Pharmacy Continence Care Project (Australia), 1649
phase I-IV trials, 1718
phenol injection, transvesical, 1238
phenylephrine, FI, 1351
Phenylpropanolamine (PPA; norephedrine), SUI, 672, 673
Philippines, Continence Foundation, 1681
phosphodiesterase, 131, 658-9
inhibition, 658-9
PDE5, 659
phospholipase C, 128-9
physical consequence of obstetric fistulas, 1429
physical disability see functional impairment
physical examination
bladder pain syndrome, 1474-5
child, 706-7
nocturnal enuresis, 720
female, 341-4
non-obstetric fistulas, 1248
in FI, 354-5
male see male
neurogenic LUT dysfunction, 803
physical exercise/activity
ordinary levels of, 1667-8
SUI surgical outcome and, 1224
stressful/strenuous, 1667
FI risk and, 1331-3, 1341
POP and, 85
UI risk in men, 69
UI risk in women, 60, 1029-30
see also exercise
physical therapy see physiotherapists; physiotherapy
physicians see doctors
physiology see neurophysiology; pathophysiology
physiotherapists, 1654, 1663
physiotherapy (physical therapy)
continence awareness and promotion, 1700
trials/research, 1748-9
women with POP, 1097-100, 1108
combined with surgery, 1295-300
Pipps-Salle technique, 845
PISQ (Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire), 397
pituitary adenylate cyclase-activating peptide, 132, 198
placebos, 1750
in bladder pain syndrome, 1499
in UI
bladder training vs, 1073-4
drug therapy vs, 638-82, 1750
electrical stimulation vs, men, 1088
electrical stimulation vs, women, 1088-9
pelvic floor muscle training vs (women), 1042-3
weighted vaginal cones vs, 1056-7
plain X-rays, 551-9
plastic catheters see polyvinyl chloride catheters
plugs
anal, 869, 1530, 1612, 1615-16, 1617, 1618
urethral, 1450
Poisson distribution, 1694
Polish Continence Organisation, 1681
polyacrylamide hydrogel (Bulkamid), 1405
polydimethylsiloxane® (Bioplastique® ; Macroplastique® ) as bulking agent
anal canal, 1404
periurethral, men, 1129, 1136
polyester sling, 1215
polyethylene glycol, 1371
polyethylene terephthalate-reinforced silicon sling, 1212
polypharmacy, frail elderly, inappropriate, 982
polypropylene mesh
anterior wall surgery, 1300-1
sacrocolpopexy, 1279
polytetrafluoroethylene see PTFE
polyuria, 337
measurement, 336
nocturnal see nocturnal polyuria
polyvinyl chloride (PVC) catheters
indwelling, 1589
intermittent, 816, 1580
polyvinyl sponge, intravaginal, 1574
pons, 209-12, 220
continence centre/L-region, 212, 220
‘filling neurones’, 211
lesion and imaging studies, 220
locus coeruleus complex (LCC), 232
micturition centre (MC), 207, 209-11, 215, 216, 220, 228
see also suprapontine lesions
POPD (Pelvic Organ Protrusion Distress Inventory) and intravaginal rings and pessaries, 1103
POPD-Q exam see Pelvic Organ Prolapse - Quantification
population, target, in continence promotion programmes, 1649-52
population-based epidemiological studies
bladder pain syndrome, 1466-8
FI, 1323-30
obstetric fistulas, 1425
population-based prevention, 1666-7
porcine dermal collagen see dermal collagen
positive-pressure urethrography, 550
urethral diverticula, 603
positron emission tomography (PET) of brain, 605-7
bladder control, 217, 219
homeostatic emotions, 234
postanal repair, 1392-4, 1408
posterior pelvic compartment, ultrasonography, 567
posterior sacral rhizotomy combined with anterior root stimulation, 840
posterior sagittal approach
anorectoplasty, 1153
rectourethral fistula, 1156
posterior transsphincteric incision, rectourethral fistula repair, 1156
posterior urethral valves, 463-4
posterior urethrovesical angle, 553
post-marketing surveillance (phase IV) trials, 1718
postmenopausal women see menopausal/postmenopausal women
post-micturition/post-void
dribble see dribble
residual urine see residual urine
symptoms, definitions, 335
postnatal (postpartum) period, UI
pelvic floor muscle training in prevention and treatment, 1036-42, 1080, 1668-9
prevalence, 51-3
postpartum period see postnatal period
post-void see post-micturition
potassium chloride challenge, intravesical, 1475-6
potassium ions (and channels), 144-6
blocker, novel, 146
detrusor function and, 122, 144-5
openers, 652-3
see also calcium ion-activated potassium channels
pouches
FI (anal pouch), 1530, 1614, 1617, 1618
UI, males
guards/leafs, 1540, 1548, 1549
pouches/containers, 1528, 1567
power in trials, 1723, 1724
PPBC (Patient Perception of Bladder Condition), 387, 388
PQRST characteristics, pain evaluation, 1489
power in trials, 1723, 1724
PPBCAB, 381
pragmatic trials, 1724-5
prebiotics and FI risk, 1346-7
pregabalin
bladder pain syndrome, 1481-2
chronic pelvic pain, 1491
preganglionic neurones (PGN), parasympathetic, 198
pregnancy
as FI risk factor, 1334-7, 1340
fistulas related to see fistulas, obstetric
future/subsequent
bladder reconstruction and, 758
with obstetric anal sphincter injuries, management, 297
history see reproductive history
pelvic floor and effects of, 264-71
pelvic floor muscle training, 1036-42, 1079-80, 1688-9
pelvic organ prolapse and, 84-5, 282
UI related to, 51-3, 55-7, 264-71
pathophysiology, 264-71
prevention, 1036-42, 1668-9
research recommendations, 93
ultrasound, 570-1
see also childbirth; labour; parity; postnatal period
preoperative evaluation, men, 1124-6, 1169
pressure
anorectal, 475-91
increasing, in patients with passive FI, 1351
length of high pressure zone, 481
measurement see manometry
on voluntary contraction, 481-6
LUT
air-charged catheters for, 419-20
children, normal voiding pressure, 707
detrusor, measurement in neurogenic LUT dysfunction, 804
intravesical see intravesical pressure
leak point see leak point pressure
urethral see urethral pressure
see also pubic pressure urinals
pressure-flow studies
frail elderly, 471, 472
non-invasive methods, 420-1
pressure ulcers, 1620-1
pressure-volume studies see cystometry
prevalence (of disorders)
AI/Fl, 74, 1323-41
frail elderly, 1362, 1365
definition, 38
enuresis/wetting, night see nocturnal enuresis
obstetric fistulas, 1425
perineal dermatitis, 1619-20
POF, 80
UI (in general)
frail older and disabled persons, research, 1739
measurement issues, 86-7, 93
men, 65
post-radical prostatectomy, 1126
reasons for differences in estimates, 86-7
research recommendations, 93
women, 46-53
prevention/prophylaxis, 1645, 1666-71
FI, 1339-40, 1374, 1645, 1666-71
fistulas in women
of fistula, 1435
of postoperative UI, 1449
POF, 1670
lifestyle interventions, 1096-7
pelvic floor muscle training in, 1098
UI, 1666-70
older people, 987, 1669-70
POF surgery combined with, 1294-5
primary see primary prevention
research recommendations, 93
UI, men
electrical stimulation, 1088
magnetic stimulation, 1091
pelvic floor muscle training in, 1083-4
post-prostatectomy, 1669
scheduled voiding, 1092
UI, women
bladder training, 1071
in childbirth/postnatal, 1034-42, 1668-9
electrical stimulation, 1059
lifestyle interventions, 1028
magnetic stimulation, 1068
pelvic floor muscle training in non-obstetric patients, 1042
pelvic floor muscle training in obstetric patients, 1036-42
weighted vaginal cones, 1056
urinary tract infection
cranberry juice see cranberry supplement
indwelling catheter-related, 1593-5, 1602-4
intermittent catheter-related, 1582
in spinal cord injury, 904
PRIDE (Program to Reduce Incontinence by Diet and Exercise)
trial, 1748
primary care (and general practitioners/GPs/family doctors), 1655-6
education of physicians, 1658-60
frail elderly assessment, 975
primary outcomes in trials, 1721, 1727
primary prevention, 1666-71
FI, 1340, 1374, 1645, 1666-71
recommendations, 1671
UI, 1666-70
pelvic floor muscle training in, 1037, 1668-9
proACT™, 1131-3
probiotics and FI risk, 1346-7
cranberry supplement
procaine haematoporphyrin, 992, 995
Procon anal plug, 1613, 1615
proctography, defaecating see defaecography
proctoscopy (rectoscopy), 1308-9
proctoscopy, 355
professionals, health see health care staff
progestogens/progestins (incl. progesterone), 678
prognostic value of imaging studies, 546
Program to Reduce Incontinence by Diet and Exercise (PRIDE)
trial, 1748
prokinetic drugs (motility stimulants) in FI, 1352
neurogenic patients, 868
spinal cord injury, 907-8
prolapse
lumbar disc, 911-12
pelvic organs see pelvic organ prolapse and specific organs/tissues
prolase
proctography, defaecating
proctoscopy, 355
program to reduce incontinence by diet and exercise (pride)
prognostic value of imaging studies, 546
program to reduce incontinence by diet and exercise (pride)
trial, 1748
prokinetic drugs (motility stimulants) in FI, 1352
surgery after, in benign prostate disease, 1136-7
urodynamic studies for UI after, 451-4
see also transurethral resection
prostheses and implants
bladder neck slings/support, 846-7
historical accounts, 30
of tissue replacement materials, 149-50
see also grafts; meshes; stents and entries under artificial
proteoglycans, pelvic floor-supporting tissues, 627, 628
provocative stress testing see stress testing
PSQ (Patient Satisfaction Questionnaire), 384
psychiatric and psychological disorders, 1668
assessment of children for, 767-8
comorbid, frail elderly with UI, 970-2
enuresis/wetting
day, 45
night, 42
SUI surgical outcome with, 1224
treatment of children with, 768-9
UI risk, 1668
women, 60
psychological consequences, 1647-8
of catheter use, 1607-8
adjustment over time, 1608-9
children, 760-71
FI, 764-6, 766
reconstructive surgery, 759
UI and enuresis, 760-4, 766-71
obstetric fistulas, 1429, 1434
psychological management, nocturnal enuresis, see also specific
methods
psychological stress reduction in bladder pain syndrome, 1481
psychometric properties, questionnaires, 365-7
Psychosocial Adjustment to Illness Scale (PAIS), 398
psychotherapy, children, 768-9, 769
PTFE (polytetrafluoroethylene) as bulking agent
anal canal, 1403
periurethral, 844
indwelling catheters, 1589
as mesh for sacrocolpopexy, 1279
as sling, 1212-15
PTP (PTQ) implants, 1404
pubic pressure urinals, 1567
pubic symphysis
distance between urethral orifice and, 533
trauma in obstructed labour, 1434-3
public/consumer education and awareness, 1646, 1649-50, 1650-1,
1657-8
publications see literature
PubMed, neurogenic UI, 900
pubococcygeus muscle, 290, 475
anatomy and physiology, 475
Fl and, 281-2
assessment of muscle function, 355
pubovaginal sling, historical accounts, 28
pubdendal nerve, 186, 188
continence in sneezing and, 194
electrical stimulation of pudendal nerve afferents, 192-3
therapeutic use, 826, 830
injury see nerve injury
innervation by, 186, 188
anal and urethral rhabdosphincters, 188, 189
levator ani, 186, 188, 197
nucleus of (Onuf’s nucleus), 187, 194, 636
pudendal nerve conduction tests (incl. terminal motor
latency/PDTML), 532-3
Fl investigation, 496-7, 501
postpartum, 290, 291
pudendal somatosensory evoked potentials, 535
puerperium see postnatal period

PUF patient symptom scale, 385, 1467, 1468, 1495, 1498
pull-ups, 1540, 1542, 1553
evaluation, 1550
pulmonary disease, chronic, 60-1
frail elderly, 971
purinoceptors (and purergic nerves/innervations), 118, 130, 174,
178-80
ATP and see ATP
bladder, 150, 637
wall, and detrusor, 118
detrusor overactivity and, 262-3
P2X family, 130
P2X1, 123, 130, 636
P2X2/3, 118, 130, 178-9, 637
P2Y family, 118, 130
purple urine drainage bag syndrome, 1566
PVC catheters see polyvinyl chloride catheters
pyelography, intravenous, 548
pyridostigmine in multiple system atrophy, 885
pyrolytic carbon-coated zirconium oxide beads (Durasphere), 1404

Q

Q-tip test, 343, 343-4, 348, 1738
QT/QTc intervals
darifenacin effects, 649-50
solifenacin effects, 651
QUADAS (Quality Assessment of Diagnostic Studies), 445
quality-adjusted life years (QALY), 402-3, 1691, 1693, 1695, 1735
Quality Assessment of Diagnostic Studies (QUADAS), 445
quality of care
obstetric fistula management, 1425
obstetric fistula prevention, 1436
quality of life/QoL (and its assessment incl. health-related quality of
life), 363, 377-83
catheter-related, 817, 1606-7, 1617
children with UI, 766, 767
catheter-related, 817, 1606-7, 1617
continence devices, 1533
tercystoplasty, 853
in Fl, assessment, 393-4, 866, 1402, 1744
in Fl, in neurogenic patients, 866, 870
meningomyelocele, 915
frail elderly with UI assessing, 978
neurogenic UI (incl. detrusor overactivity)
botulinum toxin A effects, 665
in spinal cord injury, 902
in overactive bladder
darifenacin impact on, 649
fesoterodine fumarate impact on, 651-2
in POP surgical outcome assessment, 1277
tools incl. questionnaires assessing impact, 371, 373-83,
1695-6, 1734-5
children, 767
in Fl, 393-4, 866
in POP, 389-93, 397, 1746
recommendations, 1735
specific patient groups, 400-1
women after UI surgery, 1254
Quality of Well-Being Index, 1695-6
Qualiveen, 400-1
quantitative sensory testing, 334
quercetin, bladder pain syndrome, 1485
questionnaire(s), 377-83
bladder pain syndrome, 1467-8, 1494-8
continence devices, 1533
neurogenic FI, 864
patient-reported outcome, 377-403
development and validation, 364-7
recommended, 368-9
specific patient groups, 399-401
QoL see quality of life

Questionnaire for Urinary Incontinence Diagnosis (QUID), 386, 387
QUID (Questionnaire for Urinary Incontinence Diagnosis), 386, 387

QWB (Quality of Well-Being) Index, 1695-6

R

race/ethnicity
FI risk and, 1331
men, UI and, 65
nocturnal enuresis and, 41
women
pelvic dimensions and, MRI studies, 588-9
POP and, 83-4
SUI surgical outcome, 1223
UI and, 53, 64
radiation-induced conditions, pelvic
cystitis and reduced bladder capacity, 1152
FI, 354, 1338
radiography, plain film, 551-9
radioisotope scans, upper urinary tract, 549
radiology see imaging
radiotherapy, prostate cancer (and associated UI), 307-8, 452-3, 1138-40
interstitial see brachytherapy
prostate surgery and, 1138-40
see also brachytherapy; radiation-induced conditions, pelvic
random sampling, 1720
randomisation, 1720-1
randomised controlled studies (RCTs), 1716
data analysis, 1725-6
reporting, 1727-8
surgery, 1751-2
rape, traumatic fistulas, 1424
RCN (Royal College of Nursing) Continence Care Forum, 1682
real-time three-dimensional ultrasonography, 559
rectocele see vaginal wall prolapse, posterior
rectopexy, 1308-9
rectosigmoidoscopy, 355
rectourethral fistula, men, 1151, 1153-60, 1169
rectovaginal fistula, obstetric, 1433
repair, 1447
rectum
abdominoperineal resection, 802, 918
accommodation and reservoir function, 289
balloons see balloon systems
as bladder reservoir, 747
brain and, interactions, 226, 227, 231
cancer, 918
anal mucosal sensitivity following anterior resection, 491
compliance, assessment, 488, 493-6
tests, 1530, 1612-14, 1616-17, 1617, 1618
cooling test, 499
digital stimulation, 487
leak point pressure measurement, 433
micturition reflex, 525
micturition reflex, 498-9
pelvic floor, MRI grading, 590-2
urethral smooth muscle, 127
relaxation
detrusor see detrusor
pelvic floor, MRI grading, 590-2
urethral smooth muscle, 127
reliability
neurophysiological tests, 526
urodynamic studies
children, 467-8
leak point pressure measurement, 433
rehabilitation, bladder, children, 734-6, 769-71
reinnervated muscle, concentric needle EMG, 528-9
relative risk, definition, 38
reflex(es), 525
reflux, vesicoureteric see vesicoureteric reflux
regional anaesthesia, 802
fistula surgery, 1439
labour, 268-9
regression analysis, 1694
regulatory issues, questionnaires and, 367
remission, UI
men, 65
women, 53-5
Renacidin, 1598
renal problems/imaging/transplantation etc. see kidney
renography, 549
reporting of research
conflict of interest, 1757-8
randomised controlled studies, 1727-8
reproducibility
anal manometry
resting pressure, 476
squeeze pressure, 482
cystourethrography, 555-7
neurophysiological tests, 526
pad testing, 610, 618-19, 620
urodynamic studies, 423-7, 430-2
vector manometry, 487
prostatic bowel sphincter implanted around, 1398
sensation see sensation
see also anorectum and entries under transrectal
rectus fascia sling, 1211, 1212, 1215-60, 1217, 1218
vs Burch colposuspension, 1752
referral
centres, 1655
LUTS symptoms requiring, 337
reflex bladder (automatic bladder; reflex voiding; reflex incontinence), 838-42
management, 849-55
denervation, 838-42
sacral neuromodulation, 830
reflex-triggered defaecation see defaecation
reflex voiding (therapeutic use)
spontaneous, 811
triggered, 811, 813
see also reflex bladder
reflux, vesicoureteric see vesicoureteric reflux
regional anaesthesia, 802
fistula surgery, 1439
labour, 268-9
regression analysis, 1694
regulatory issues, questionnaires and, 367
remission, UI
men, 65
women, 53-5
Renacidin, 1598
renal problems/imaging/transplantation etc. see kidney
renography, 549
reporting of research
conflict of interest, 1757-8
randomised controlled studies, 1727-8
reproducibility
anal manometry
resting pressure, 476
squeeze pressure, 482
cystourethrography, 555-7
neurophysiological tests, 526
pad testing, 610, 618-19, 620
urodynamic studies, 423-7, 430-2

1856
children, 467-8
neurogenic LUT dysfunction, 456-7
reproductive history (pregnancy/obstetric history), research relating to, 1737
frail older and disabled people, 1739
reproductive organs see genitalia/genital organs
reproductive performance and obstetric fistulas, 1432-3
research (incl. future/further research needs and recommendations), 1713-65
bladder pain syndrome, 1502-3, 1744-5
catheters
indwelling, 1611
intermittent, 817, 1611
children, 1741-2
continence devices (UI and FI), 1556
urodynamic studies, 468
conservative treatment
with continence devices see subheading below
men, 1094-5
women, 1081-2
continence awareness and promotion, 1651-2, 1658
continence devices, FI, 1618
children, 1556
continence devices, UI, 1749-50
absorbent products for light UI in females, 1546
absorbent products for light UI in males, 1548
absorbent products for moderate/heavy UI, 1554
adherence to trial design criteria, 1755
bodyworn urinals, 1567
children with UI and/or FI, 1556
commodes and bedpans, 1537
handheld urinals, 1535
mechanical devices for females, 1570, 1572, 1575
mechanical devices for males, 1576
penile sheaths, 1561
product evaluation methodology, 1531-3
underpads, disposable, 1555
underpads, washable, 1555
urine drainage bags, 1566-7
dementia and UI
Alzheimer’s disease, 879
frontotemporal dementia, 882
Lewy body dementia, 881
vascular dementia, 880
on economic analysis, 1708-9
endoscopy, 610
epidemiological, 92-4
FI, 93-4
POP, 93-4
UI, 64, 92-3
ethical considerations, 1756-8
FI, 1744-5
assessment of FI, 355
biofeedback and anal sphincter/pelvic floor training, 1359, 1375-6
bowel training, 1350, 1375
continence devices see FI (subheading above)
diet and fluid intake, 1348, 1375
drug therapy, 1352, 1375
electrical stimulation, 1360, 1376
epidemiological studies, 93-4
imaging, 616-17
lifestyle factors and education, 1343, 1374
in neurological disease see subheading below
older people, 1373
prevention of FI, 1341, 1374
QoL, 870
general recommendations, 1716-29
goals, 1715
imaging, 549
cystourethrography, 557
FI, 616-17
MRI, 594
open bladder neck and proximal urethra, 602
residual urine evaluation, 599
urethral diverticula, 604
LUT (in general), 151
LUTS (in general), 337, 1736-9
men, 1736-7
outcomes measurement, 1729-36
women, 1737-9
neurogenic UI, 1742-4
intermittent catheterisation, 817
neurological disorders causing see subheading below
triggered reflex bladder, 811
neurological disorders (FI or UI due to)
cerebral lesions and cerebrovascular accidents, 892
dementia see subheading above
in diabetes mellitus, 917
Guillain-Barré syndrome, 910-11, 911
HIV disease, 922
iatrogenic, 919
meningomyelocele, 914
multiple system atrophy, 885, 886
Parkinson’s disease, 888, 890
spinal cord injury, 904-5, 908
neurophysiological tests, 538
nocturia, 1747-8
odour control products, 1628
older people (incl. frail persons)
with FI, 1373
with UI, 311, 1006-7, 1009-10, 1739
outcomes, 1658
LUTS, 1729-36
patient-reported outcome questionnaires, 403
pad testing, 623
pelvic floor, 197
pharmacotherapy see drug therapy
physical examination
females, 349
males, 353
POP, 1746-7
epidemiology, 93-4
treatment, 1310-11
post-void residual volume testing, 340
professional education, 1665
skin care products, 1626
surgery, 1751-5
adherence to trial design criteria, 1755
frail older people, 1740
men, 1170
in new procedures, 1753-4
women with POP, 1310-11
tissue replacement/engineering, 149-51
translational, 149
urinalysis, 338
urodynamic studies
air-charged catheters for pressure measurements, 420
children, 468
detrusor overactivity, 439, 441, 442
geriatric patients, 471, 473
men, 453-4
in neurogenic LUT dysfunction, 457, 1743
reproducibility of results, 426
in therapeutic response prediction, 442
women, 445, 446, 449-50
see also literature; trials
Resident Assessment Instrument and Resident Assessment Protocol, 1005
residential care see nursing home
residual urine (post-void; PVR), evaluation, 338-40, 562-4, 597-9
children, 709-10
imaging, 597-9
ultrasound see ultrasound
rupture, reservoir, 755
Royal College of Nursing Continence Care Forum, 1682
routine care costs, 1700-1
Romans, ancient, 21
ROK
ROCK
robotic surgery, POP, 1278
rho-associated kinase (ROK/ROCK), 121-2
rhizotomy, sacral
rhizotomy, sacral see sacral rhizotomy
rho-associated kinase (ROK/ROCK), 121-2
anal sphincter and, 139
risk of disorders, factors affecting see aetiology
of procedures see safety
relative, definition, 38
robotic surgery, POP, 1278
ROK see rho-associated kinase
ROM see rho-associated kinase
Romans, ancient, 21
routine care costs, 1700-1
Royal College of Nursing Continence Care Forum, 1682
rupture, reservoir, 755
Sacral agenesis, 460-1
neurogenic detrusor-sphincter dysfunction, 741
urodynamic studies, 461-2
sacral cord dysfunction and FI, 1366
sacral nerve root(s)
afferent nerve recording from, 810
electrical stimulation see sacral neuromodulation
magnetic stimulation see magnetic stimulation surgery, 839-42
sacral neuromodulation (therapeutic electrical nerve root stimulation), 829-32, 1242-5
anterior (cauda equina stimulation), 533
with posterior sacral rhizotomy, 840
bladder pain syndrome, 1488-9
children, 736
complications see safety aspects
in detrusor overactivity, 1149
FL, 1359, 1399-402, 1408
cost-benefit, 1402
mechanism of action, 1400
neurogenic see subheading below
outcome, 1400-2
patient selection and indications, 1399-400
safety, 1402
technique, 1399
neurogenic FL, 871-2
meningomyelocele, 915
neurogenic LUT dysfunction, 829-32
hypotheses on mode of action, 829-30
posterior/dorsal, section see sacral rhizotomy
in spinal cord injury, 904
sacral parasympathetic nucleus (SPN), 198, 202
sacral reflexes, 525-6
see also bulbar-cavernous reflex
sacral rhizotomy, 839, 1239
combined with anterior root stimulation, 840
sacral spinal cord dysfunction, FL, 1366
sacral spine, imaging, 605
sacrococcygeal suspension, 1277, 1278, 1279-86
Burch colposuspension added to, 1754
outcomes, 1281-5
sacral perineal-sacroabdomino-perineal pull-through, 1153
sacrospinous ligament suspension or colpopexy, 1280, 1286, 1287
vs sacral colpopexy, 1707
safety aspects (incl. adverse effects and complications)
adjustable balloons (for urethral compression), 1133
antegrade continence enemas, 1407
artificial urinary sphincter, 1161-3
bladder reconstruction, 755-9
continence devices, 1750
cryosurgical ablation of prostate, 1140-1
neurogenic detrusor overactivity in women, 1242-5
neurogenic FI, 871-2
1141
399
fistula repair, 1448, 1452
indwelling suprapubic catheters, 819
indwelling urethral catheters see indwelling catheters
intermittent catheterisation see intermittent catheterisation
male sling, 1131
neuromodulation (sacral nerve stimulation)
in FL, 1402
in UI, 1244
POP surgery
with concomitant hysterectomy, 1294
related to route, 1278
surgery (in general), 1754
children, 755-9
fin detrusor overactivity in women, 1242-5
new procedures, 1754
for SUI in women, 1222, 1223, 1229-37
in trials, 1757
monitoring, 1722
triggered reflex voiding, 811
urinary diversion
continent, 856
non-continent, 858-9, 859-60
see also drug-induced incontinence
saline 0.9% (catheter maintenance solution), 1598
saline retention test, 493
sampling
methods/strategies, 1720
sample size considerations, 1723-4
in UI prevalence estimation, 47
satisfaction with treatment see treatment
scaffold for tissue-engineered grafts, 150, 750
scheduled voiding
men, 1092-3

Sacral agenesis, 460-1
neurogenic detrusor-sphincter dysfunction, 741
urodynamic studies, 461-2
sacral cord dysfunction and FI, 1366
sacral nerve root(s)
afferent nerve recording from, 810
electrical stimulation see sacral neuromodulation
magnetic stimulation see magnetic stimulation surgery, 839-42
sacral neuromodulation (therapeutic electrical nerve root stimulation), 829-32, 1242-5
anterior (cauda equina stimulation), 533
with posterior sacral rhizotomy, 840
bladder pain syndrome, 1488-9
children, 736
complications see safety aspects
in detrusor overactivity, 1149
FL, 1359, 1399-402, 1408
cost-benefit, 1402
mechanism of action, 1400
neurogenic see subheading below
outcome, 1400-2
patient selection and indications, 1399-400
safety, 1402
technique, 1399
neurogenic FL, 871-2
meningomyelocele, 915
neurogenic LUT dysfunction, 829-32
hypotheses on mode of action, 829-30
posterior/dorsal, section see sacral rhizotomy
in spinal cord injury, 904
sacral parasympathetic nucleus (SPN), 198, 202
sacral reflexes, 525-6
see also bulbar-cavernous reflex
sacral rhizotomy, 839, 1239
combined with anterior root stimulation, 840
sacral spinal cord dysfunction, FL, 1366
sacral spine, imaging, 605
sacrococcygeal suspension, 1277, 1278, 1279-86
Burch colposuspension added to, 1754
outcomes, 1281-5
sacral perineal-sacroabdomino-perineal pull-through, 1153
sacrospinous ligament suspension or colpopexy, 1280, 1286, 1287
vs sacral colpopexy, 1707
safety aspects (incl. adverse effects and complications)
adjustable balloons (for urethral compression), 1133
antegrade continence enemas, 1407
artificial urinary sphincter, 1161-3
bladder reconstruction, 755-9
continence devices, 1750
cryosurgical ablation of prostate, 1140-1
neurogenic detrusor overactivity in women, 1242-5
neurogenic FI, 871-2
1141
399
fistula repair, 1448, 1452
indwelling suprapubic catheters, 819
indwelling urethral catheters see indwelling catheters
intermittent catheterisation see intermittent catheterisation
male sling, 1131
neuromodulation (sacral nerve stimulation)
in FL, 1402
in UI, 1244
POP surgery
with concomitant hysterectomy, 1294
related to route, 1278
surgery (in general), 1754
children, 755-9
fin detrusor overactivity in women, 1242-5
new procedures, 1754
for SUI in women, 1222, 1223, 1229-37
in trials, 1757
monitoring, 1722
triggered reflex voiding, 811
urinary diversion
continent, 856
non-continent, 858-9, 859-60
see also drug-induced incontinence
saline 0.9% (catheter maintenance solution), 1598
saline retention test, 493
sampling
methods/strategies, 1720
sample size considerations, 1723-4
in UI prevalence estimation, 47
satisfaction with treatment see treatment
scaffold for tissue-engineered grafts, 150, 750
scheduled voiding
men, 1092-3
scheduled voiding, women, see also timed voiding
scheduled waking, 724
scintigraphy (isotope scans), upper urinary tract, 549
Schweizerische Gesellschaft fur Blasenschwache (Switzerland), 1682
Sciatric (sciatic) nerves, 337
Sciatric nerve, 337
Sciatric nerve palsy, 337
Sciatric (sciatic) nerves, 337
Screening
for FI in high-risk groups, active, 1524
tools and questionnaires, 383-8
children, 767-8
scrotal approach, artificial urinary sphincter implantation, 1161-3
secretory properties, urothelium/suburothelium, 117-19
Sex hormones/steroids
in UI treatment, 676-9
urethral smooth muscle relaxation, 127
see also oestrogen; progestogens
Sexual abuse (children/women)
fistula related to, 1424
urinary symptoms, 740
sexual dysfunction, 1738
assessment/evaluation for see sexual function/satisfaction
mode of delivery and, 267
POP and, 285
surgical management of, 1276
SUI surgery-related, 1236
symptoms associated with, 341
sexual function/satisfaction, evaluation, 395-9
men, 395, 396, 398-9
questionnaires in, 371, 395-9
women, 395, 396, 397-8, 398, 399, 1738
sexual intercourse (coitus)
assessment/evaluation for see sexual function/satisfaction
mode of delivery and, 267
POP and, 285
surgical management of, 1276
SUI surgery-related, 1236
symptoms associated with, 341
sexual function/satisfaction, evaluation, 395-9
men, 395, 396, 398-9
questionnaires in, 371, 395-9
women, 395, 396, 397-8, 398, 399, 1738
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
Sexual Quality of Life-Female Questionnaire (SQOL-F), 399
sexuality
women, 1070-8
silicone urethral inserts, 1570-2
silver alloy-coated indwelling catheters, 1586, 1589, 1593, 1594, 1597, 1601, 1602
Simon, Gustav, 26
Simon Foundation for Continence, 1683
Sims, Marion, 26
Singapore, Society for Continence, 1681
single blind trial, 1722
single fibre EMG, 529
single photon emission tomography (SPECT), CNS, 605-7
Sinoba (Sweden), 1682
SISTEr (Stress Incontinence Surgical Treatment Efficacy Trial), 1752
six transmembrane (6TM) family of receptors, 144-6
skeletal muscle
anal sphincter see anal sphincter, external disease, EMG, 531-2
urethral see urethral sphincter, external
see also muscle
Skene AJC, 1462, 1463
skin
fistula between, and urethra, men, 1151-3, 1169
health (and continence products), 1618-26
pads, 1556
obstetric fistula-related injury, 1434
sympathetic response see sympathetic nervous system
urinary diversion to continent, 855-7
non-continent 860-1, 855-7
sleep, children
arousal from see arousal; waking nocturnal enuresis and, 42
sleep apnoea
children, 42
frail elderly, 971
sling procedures (sub-urethral), 1211-17
children, 752
historical accounts, 28-9
materials, 1211-12, 1212-16
men
post-prostatectomy, 453, 1129-31, 1132, 1136-7
post-radiotherapy, 1139
neurogenic LUT dysfunction, 846-7
ultrasound, 571
women, 1211-17, 1289, 1290
Burch colposuspension vs, 1752
concomitant to other surgery, 1295
mid-urethral tapes vs, 1218
vaginal extrusion of sling material, 1235
Slovakia, continence organisation, 1682
slow stream, definition, 335
smells, masking products, 1626-8
smoking, 1031, 1668
as FI risk factor, 1341-2
as UI risk factor, 1668
women, 60-1, 1031
smooth muscle (LUT)
active properties, 135-6
anorectum, 138-9
bladder wall/detrusor see detrusor EMG, 537
urethral, 127
vaginal wall/supportive tissues, alterations in POP, 280-1
smooth muscle myosin (SM) in detrusor contraction, 121
smooth muscle relaxants see bladder relaxants
SNARES (soluble N-ethyl maleimide sensitive-factor attachment protein receptors), 661
sneezing, continence in, neural mechanisms, 194
Soave procedure, 1160
social consequences, obstetric fistula, 1429
social factors
nocturnal enuresis, 42
see also cultural aspects
Society for Continence, Singapore, 1681
Society of Urologic Nurses see specific Associates, 1683
socioeconomic factors, POP, 85
sociomedical factors, obstetric fistulas, 1426, 1428
sodium ion channels
epithelial, 144
non-neurogenic detrusor overactivity and, 260
NGF and TTX-resistant, 182
sodium pentosan polysulfate see pentosan polysulfate solabegron, 658
solifenacin (YM905), 650-1, 822, 1703
economic analysis, 1702, 1703
frail elderly, 993-4
soluble N-ethyl maleimide sensitive-factor attachment protein receptors (SNAREs), 661
Solution G, 1598
Solution R, 1598
somatic motor system and somatic innervation, 636, 797
tests, 527-33
somatosensory evoked potentials, 534-5, 818
sodium pentosan polysulfate see pentosan polysulfate
Society of Urologic Nurses see specific Associates, 1683
South Africa, Continence Association, 1682
South Korea, continence organisation, 1681
Spain, continence organisation, 1682
SPARC (suprapubic arc sling), 1218, 1219
specialists (and specialist centers) in continence care
nurses, 1654-5, 1661-2, 1663
single specialist model, 1654
training of physicians, 1661
fistula care in developing world, 1450
referral, LUTS symptoms requiring, 337
SPECT, CNS, 605-7
SpediCath, 816
Spence technique, 1247
sphincter see anal sphincter; urethral sphincter
sphincteroplasty, anal, 1391-3, 1408
sphincterotomy
internal anal, FI risk, 1338
urethral, 833-8
endoscopic, 833-5, 837
prosthetic, 835-7, 838
SPI (Symptom Problem Index), 388
spina bifida, 912-16
spinal anaesthesia, fistula surgery, 1439
spinal anaesthesia, fistula surgery, 1439
spinal canal stenosis, 801, 908-9
spinal cord
afferent neurones, 182-4, 227
developmental abnormalities (myelodysplasia), 457-9, 740, 741, 912-16
efferent pathways to bladder, 198, 200-2
evoked potentials, epidural recording, 810
glial cells, 183-4
sacral see sacral spinal cord
see also ascending pathways; descending pathways
spinal cord lesions (incl. injury/SCI), 799, 801, 862, 898-908
catheters and, 1606-7
indwelling, 901, 903, 1606-7
intermittent, 902, 903
conservative treatment, 811-12
detrusor overactivity, 258-9
electrical stimulation with, 24
FI due to, 799, 862, 906-7, 1338-9, 1366
colostomy, 877
diagnosis, 864
patient-reported outcome assessment, 400-1
urine storage abnormalities, 223
urodynamic studies, 900-1
children, 461-2
spinal dysraphism, 459-60
detrusor-sphincter dysfunction, 740
imaging, 605, 606
occult, 459-60
physical examination, 707
urodynamic studies, 459-60
spinal reflexes, 227-8, 803
anal and urethral rhabdosphincters and, 189, 192
assessment, 803
lamina I afferent input to, 227
spinal urine-storage-reflex inhibitory center (SUSRIC), 192-4
spine
discs see intervertebral disc disease
'imaging, 605-6
'spinning-top' configuration, 711
spinobulbospinal reflex, 215
spino-thalamic input
to interoceptive cortex, 230
to limbic behavioural motor cortex, 230
sponge, intravaginal polyvinyl, 1574
spontaneously hypertensive rat, 223
SQOL-F (Sexual Quality of Life-Female Questionnaire), 399
squeeze pressure measurements (external anal sphincter), 481-5
SSI (Symptom Severity Index), 388
staff
health care see health care staff
nursing home see nursing home
staining with washable pads, faecal, 1557
Stamey grading scale, 1749
Stamey needle suspension/colposuspension, 1202, 1203, 1212, 1216
standard error of the coefficient, 1694
standard setting for nurses, 1662
Standards for Reporting of Diagnostic Accuracy (STARD), 545
STAR trial, 651
statistical analysis, 1694
trials, 1718-29
recommendations, 1729
stem cells, transurethral injection
post-radical prostatectomy, 1129
ultrasoundography-guided, 572
stents, urethral sphincter, 835-7, 838
steroid hormone therapy in UI, 676-9
stoma, continent
child, 754-5
complications
continent urinary diversion, 856
non-continent urinary diversion, 859
cutaneous site, 855-7
other types, 857
stomach, bladder reconstruction/augmentation using (gastrocysto
plasty), 853-4
child, 748
malignancy complications, 758-9
stones (calculi/lithiasis), urinary (incl. kidney/bladder)
cystoplasty and, 757-8
indwelling catheters and, 1599
intermittent catheters and, 1583
multiple sclerosis, 896
non-continent urinary diversion and, 859
spinal cord injury, 901-2
vesicovaginal fistula-associated, 1430
stools see faeces
storage (urine)
capability, intravesical pressure measurements in assessment of,
peripheral control, 634
storage dysfunction/failure, 222-4, 633, 636
children
postoperative, 755

surgery, 745, 746
neural mechanisms, 222-4, 636
storage reflexes (urine), 192-4
storage symptoms, definitions, 334-5
strain-softening phenomenon, 134-5
straining (defaecation), chronic, 354
straining (voiding)
definition, 335
urothelial axis during, 553
stratification/stratified sampling, 1721
stream
intermittent, definition, 335
slow, definition, 335
strength, pelvic floor muscle see pelvic floor muscle
strength-duration test, external anal sphincter, 497-8
Strengthening of the Reporting of OBservational studies in
Epidemiology (STROBE) statement, 92
stress
pelvic floor, chronic, 283
psychological, reduction in bladder pain syndrome, 1481
stress incontinence (SUI - females), 27-9, 1193-237, 1701-2
conservative treatment, economic analysis, 1700-1
definition of, 334
drug therapy, 672-5
hormonal, 676-7, 678
electrical stimulation in
men, 1088
women, 1060, 1061, 1062, 1063-4, 1065, 1066
EMG changes, 531-2
frail elderly, 470
imaging, 276-8
initial assessment, 342
magnetic stimulation in, 1065, 1069, 1070
mixed UUI and see mixed UI
neural mechanisms, 224
obstetric causes/risk factors, 264, 265-6, 267, 272-3
pathophysiology, 271-8
pelvic floor muscle training, 1042, 1066
biological rationales for, 1034-5
recommendations for practice, 1080
pelvic floor properties and, 135
POP comorbid with, surgical considerations, 1228-9
POP surgery and prevention or treatment of, 1294-5, 1296-9
postoperative, in POP patients, 448
selection of treatment, leak point pressure in, 433-4
severity, assessment, 443-4
surgery, 842-9, 1193-237, 1701-2, 1751, 1754
complications, 1222, 1223, 1229-37
concomitant urethral diverticulectomy, 1246
confounding variables, 1220-8
economic analysis, 1697-8, 1701-2
historical accounts, 27-9
men, 1161
predicting failure, 446
for recurrence, outcome, 1224-6
in sphincteric incompetence, 842-9
trials, 1751, 1754
urgency after, 447
voiding difficulties after, 446-7
urodynamic studies, 442-8
with coexisting overactive bladder, 436
diagnostic and therapeutic value, 433-4
leak point pressure, 433
women, 442-8
vaginal cones, 1080
stress incontinence (SUI - males)
drug therapy, 675
stem cell therapy, 572
Stress Incontinence Surgical Treatment Efficacy Trial (SISTEr),
novel, 1161
stress response, endoplasmic reticulum, 146-8
stress testing (provocation tests)
in detrusor overactivity, 439-40
frail elderly, 977
women, 342
after UI surgery, 1253
Stress/Urge Incontinence Questionnaire, 390
stretch, urothelial response to, 117, 118, 120, 122, 134
strictures, urethral see urethral strictures
STROBE (Strengthening of the Reporting of OBServational studies in Epidemiology) statement, 92
stroke see cerebrovascular accident
subcortical areas in bladder control, 216-20
subjective measures in outcomes research, ICS Standardization Committee recommendations, 1730-1
subsacral lesions, 799
substance P (SP), 179, 182, 195, 202
subthalamic nucleus deep brain stimulation, 827
subthalamic lesions, 802, 918
nerve damage due to, 802, 918
neurogenic LUT dysfunction, 829-61
neurogenic LUT dysfunction, 829-61
new procedures, development and assessment, 1753-4
older people/frail elderly, 995-7, 1008-9
complications in SUI surgery, 1232
men, 1137-8
recommendations, 1008-9
research, 1740
pelvic see pelvic surgery
pelvic floor (in general), ultrasound, 571
pelvic organ (incl. vaginal) prolapse, 1273-320, 1706-7
new technologies, 1170
older people, 1137-8
post-prostatectomy in benign disease, 1136-7, 1169
post-prostatectomy in cancer, 1128-35, 1137-8, 1169
post-radiotherapy, 1139-40
fistulas (not specifically in women)
SUSRIC (spinal urine-storage-reflex inhibitory center), 192-4
suspension systems, urine drainage bags, 1564
Sweden
Enuresis Trial (SWEET) Group, 722
patient-reported outcome assessment in older patients, 400
Swedish Urotherapists, 1682
SWEET study, 722
Switzerland, continence organisation, 1682
sympathetic nervous system, 797
cutaneous, response and its assessment, 537
diabetes mellitus, 916-17
neurogenic LUT dysfunction (in general), 811
denervation in bladder pain syndrome, 1493
LUT, 634
anorectum, 138
bladder base and trigone, 126
urethra, 127
see also autonomic nervous system
symphysis pubis see pubic symphysis
symptom(s)
in bladder pain syndrome, assessment, 1475, 1494-8
bowel see bowel symptoms
FI
older people, 1369
questionnaires assessing, 393-4
in POP, 285, 341, 1276-8
in outcome assessment, 1276, 1746
symptom(s), LUT, 334-7
assessment/quantification, 335-7
females, 340-1
frail older people, 1010-11
frequency and severity of symptoms, 335-7
in ICI modular questionnaire, 371
males, 351
in patient-reported outcome assessment, 364-7, 377-403
in POP, 389-93, 397, 1746
postoperatively in women having UI surgery, 1253-4
in QoL studies see subheading below
men
age-related occurrence, 970
assessment, 351
research, 1736-7
as risk factor for UI, 69
in POP surgical outcome assessment, 1276
requiring specialist referral, 337
research see research
screening tools, 383-8
severity see severity
UI categorised by, 336
urinalysis, 337-8
women
in pregnancy, 265
in prolapse, 341, 1737-8
research, 1737-9
as risk factor for UI, 59
worldwide estimates of numbers of individuals with, 89
see also bothersomeness
Symptom Impact Index (SII), 388
Symptom Problem Index (SPI), 388
Symptom Severity Index (SSI), 388
synbiotics and FI risk, 1346-7
synthetic materials
anterior wall prolapse repair, 1300-1
apical prolapse repair (by sacrocolpopexy), 1279
slings, 1212-15
systemic lupus erythematosus, 801, 920

T

T-shaped pads/diaper, 1542, 1553
tachykinin(s), 132, 179-80
micturition and, 183

see also specific types
tadalafil, 659
Taiwan Continence Society, 1682
tampon-type bladder neck support devices, 1572
tamsulosin, 657, 824
tap(s), drainage bags, 1562, 1563
see also valves
tape
suburethral, 842-3
tension-free vaginal see tension-free vaginal tape
target difference, 1723-4
TBS (Treatment Benefit Scale), 384
temperature sensation tests see ice water/test; thermal testing
10-Item Scale to Measure Urinary Urgency, 391
tension, bladder wall/detrusor, and its generation, 132, 136-7
tension-free vaginal tape (TVT; mid-urethral tapes), 842-3, 1217-20
alternative procedures to, 1193-217
alternative procedures vs, 1218-20
cost-effectiveness of, 1697-8
randomised controlled trials, 1217, 1219, 1752, 1753
complications, 1231, 1232, 1233, 1234
obesity-related, 1223-4
for POP with SUI, 1229
for recurrent SUI, 1225
tension-free vaginal tape-obturator (TVT-O), 1219, 1220
terbutaline
overactive bladder symptoms/detrusor overactivity, 658
SUI, 673
terminal dribble see dribble
terminal node (decision tree), 1692
terminology see definitions and terminology
terodiline, 653
children, 739
tertiary prevention of UI, 1037
test-retest reliability
questionnaires, 366
urodynamic studies, 423-4
tetrodotoxin-resistant Na+ channels, 182
Thailand, continence organisation, 1682
thalamic deep brain stimulation, 827
thalamocortical relay units (ventromedial thalamic nuclei), 230, 231
therapy see treatment
thermal ablation of prostate, UI risk, urodynamic studies, 451
thermal testing, anorectal, 492-3
see also ice water/test
three-dimensional MRI, 579
three-dimensional ultrasonography, 559
Three Incontinence Questions Questionnaire, 386
three-state Markov model, 1693
thromboxane A2 receptors, 142
tibial nerve stimulation, posterior, 826, 1402-3, 1408
tic douloureux, 1462, 1463
timed voiding, 815
frail elderly, 985, 986, 987
men, 1092
women, 1077
recommendations for practice, 1081
Timms C3 penile compression device, 1576
tissue adhesives, non-obstetric fistulas, 1249
tissue analysis, 627-9
tissue engineering and replacement, 149-51, 750
bladder (tissue-engineered neobladder), 150, 750
child, 150
in detrusor overactivity, 1240
tobacco smoking see smoking
toilet facilities and FI risk, 1342
older people, 1369
toilet training, children, 1349
toileting (and toileting assistance incl. habit training)
devices/products assisting with, 1522, 1526, 1533-7
FI, neurogenic, 868-9, 907
neurogenic UI, 814-15
24-hour production, measurement, 336
twin studies, POP, 84
twisting of external continence devices see anti-kinking features
two-hour pad test, 620

U

U-Control vzw, 1680
UDI (Urogenital Distress Inventory) and UDI-6, 382, 382-3, 387, 389, 390
UHAI (Urinary Incontinence Handicap Inventory), 381
UIS (Urinary Incontinence Score), 381
UISS (Urinary Incontinence Severity Score), 381
UITN (Urinary Incontinence Treatment Network), 1752, 1754
UK see United Kingdom
ulcer(s), pressure, 1620-1
ulcerative colitis and FI, 1334
ultrasound, anal (in FI), 486, 487
ultrasound, transrectal high-intensity focused, 1140-1, 1155
ultrasound, urinary tract (and pelvic floor and its dysfunction), 557,
ultrasound, bladder neck, 561-2
ultrasound, endoanal/transanal (EAUS), 480, 487, 498, 611, 614, 616
ultrasound, transrectal high-intensity focused, 1140-1, 1155
ultrasound, urinary tract (and pelvic floor and its dysfunction), 557,
ultrasound, bladder neck, 561-2
ultrasound, endoanal/transanal (EAUS), 480, 487, 498, 611, 614, 616
ultrasound, transrectal high-intensity focused, 1140-1, 1155
ultrasound, urinary tract (and pelvic floor and its dysfunction), 557,
ultrasound, bladder neck, 561-2
ultrasound, endoanal/transanal (EAUS), 480, 487, 498, 611, 614, 616
ultrasound, transrectal high-intensity focused, 1140-1, 1155
ultrasound, urinary tract (and pelvic floor and its dysfunction), 557,
ultrasound, bladder neck, 561-2
ultrasound, endoanal/transanal (EAUS), 480, 487, 498, 611, 614, 616
ultrasound, transrectal high-intensity focused, 1140-1, 1155
ultrasound, urinary tract (and pelvic floor and its dysfunction), 557,
ultrasound, bladder neck, 561-2
ultrasound, endoanal/transanal (EAUS), 480, 487, 498, 611, 614, 616
ultrasound, transrectal high-intensity focused, 1140-1, 1155
ultrasound, urinary tract (and pelvic floor and its dysfunction), 557,
ultrasound, bladder neck, 561-2
ultrasound, endoanal/transanal (EAUS), 480, 487, 498, 611, 614, 616
ultrasound, transrectal high-intensity focused, 1140-1, 1155
ultrasound, urinary tract (and pelvic floor and its dysfunction), 557,
urethral strictures, 465
urethrectomy and cystectomy, urinary diversion with/without, in urethral valves, posterior, 463-4
closure pressure
urethral orifice/opening/meatus
urethral meatus
urethral plugs, 1450
urethral pressure, 422-3
closure pressure see urethral closure pressure measurements/studies, 419, 422-3
reproducibility/reliability/normal values, 430-2
retrograde see retro-resistance pressure urethral pressure profile (UPP) and its assessment, 419, 423
urethral resistance studies, 275
urethral sphincter, external/distal (rhabdosphincter; urethral skeletal muscle), 128
areflexia see underactive urethral sphincters artificial see artificial sphincter bypass procedures, children, 746-7
contraction, detrusor relaxation and, co-ordination, abnormalities see detrusor-sphincter dysfunction; detrusor-sphincter dysynergia control, development, 703-4
EMG, 275
in multiple system atrophy, 884
in neurogenic LUT dysfunction, 808
in spinal urine-storage-reflex inhibitory center characterisation, 192-3
females, anatomy/location, 271
function, mechanism, 300-2
incompetence see underactive urethral sphincters innervation, 188-92, 301
neurochemical anatomy of motor neurones, 194
intrinsic sphincter deficiency (ISD), 273-8
concept of, 273-4
hypermobility vs, 274-8
urodynamics in the frail elderly, 470-1
neurogenic deficiency, drug therapy, 820, 824-5
neurophysiological studies, 275
EMG see subheading above overactive see overactive urethral sphincters pharmacology, 194-7
supraspinal activation, 193-4
surgery, 833-8
underactive see underactive urethral sphincters see also vesicourethral disorders urethral sphincter, internal/proximal, 300, 301
urethral sphincter dysfunction (incl. incompetence) men, rarity of UI due to, 1736
neurogenic see neurogenic sphincter dysfunction paediatric/congenital causes, surgery, 745-6, 746
post-prostatectomy, 306-7, 1124
endoscopic assessment for, 609
urethral strictures, 465
with intermittent catheterisation, 1582-3
urodynamics in children, 465
urethral valves, posterior, 463-4
urethrectomy and cystectomy, urinary diversion with/without, in

bladder pain syndrome, 1494
urethrocutaneous fistula, men, 1151-3, 1169
urethreography diverticula, 603, 1246
positive-pressure, 550
see also cystourethreography urethropelvic angle, 553
urethroperineal fistula, surgery, 1406-7
urethrovaginal fistula, men, 1151, 1153-60, 1169
urethroscopy, Q-tip test and, 343
see also endoscopy urethrovaginal fistula, non-obstetric, 1251-2
evaluation, 1248
repair, 1252
urethrovaginal fistula, posterior, 553
urethrovaginal fistula see bladder neck
urge FI, 353
Urgency Impact Scale (URIS) and URIS-24, 390, 400
urge syndrome see overactive bladder
urge UI (UI; urgency UI), 448-9
children
behavioural disorders and, 764
urotherapy, 769
definition, 334
depression and see depression detrusor overactivity and, association between, 436
drug therapy antimuscarinics, 645
oestrogens, 677-8
frail older people, 469-70
gender and, see also men; women (subheadings below)
magnetic stimulation, 1069, 1070
men
conservative treatment, 1088
prevalence, 65
refractory, management, 1145-9, 1169
mixed SUI and see mixed UI
pathophysiology, 448-9
severity, 448-9
women, 448-9
electrical stimulation, 1060, 1061
pelvic floor muscle training, 1035, 1080
and POP, surgical considerations, 1229
urodynamic studies, 448
urgency (to defaecate)
FI risk related to, 1334
resisting, 1348-9
urgency (to urinate)
bladder training, 1078
definition, 334
drug therapy antimuscarinics, 647, 649, 651
resiniferatoxin, 668
electrical stimulation, 1061, 1062
measurement, 336
measurement of impact of, 381, 387-9, 390, 390-1
postoperative, in SUI, prediction, 447
UI see overactive bladder
urgency/frequency (U/F), sacral nerve stimulation, 1242-4
Urgency Perception Scale/Score (UPS), 387-9, 390
Urgency Questionnaire (UQ), 381
Urgency Rating Scale (URS), 389, 390
urgency UI see urge UI
uridine triphosphate (UTP), 120
uridomes see condom catheters
urinals (devices), 23, 25, 1533-5
bodyworn see bodyworn continence devices
handheld, 1526, 1533-5
urinalysis, 337-8, 625-6
children, 707
males, 352
urinary diary see frequency/volume diary
urinary diversion
  in bladder pain syndrome, cystectomy and urethrectomy
  with/without, 1494
continental see continental urinary diversion
in detrusor overactivity, 1240
in developing world (in fistula management), 1447-8
with extrophy/epispadias complex, 1144-5
historical accounts, 29
non-continental see non-continental urinary diversion
with rectourethral fistula, 1155
urinary incontinence (UI - major refs only)
aetiology see aetiology
artificial urinary sphincter complicated by, 1163
assessment see assessment
children see children
classification by symptoms, 336
conservative management see conservative/medical management
definition, 334
devices for see continence devices
drug therapy see drug therapy
epidemiology see epidemiology
episode frequency, assessment, 336
extra-urethral, endoscopy, 609
FI and, association, 1333
guidelines, 1664-5
help-seeking see help-seeking behaviour
historical perspectives, 19-34
imaging see imaging
impact and consequences, 61-2
LUTS with, urodynamic studies in men, 450-1
men see males
neurological causes see neurogenic LUT dysfunction and incontinence
obstetric see childbirth; pregnancy
odour control products, 1626
older people see frail elderly; older people
open bladder with (OAB_dry), 72
overactive bladder (OAB) see overactive bladder
overflow, urodynamic studies, 456
pathophysiology, 257-78, 299-311, 799
men, 299-308
men, post-prostatectomy, 1128
women, 271-8, 448-9
women, post-fistula repair, 1448
POP comorbid with see pelvic organ prolapse
post-fistula repair, 1448-50
prevention see prevention
reflex see reflex bladder
screening tools, 383-8
severity see severity
surgery see surgery
transient see transient UI
types, 334
  continuous, definition, 334
  mixed see mixed UI
urinalysis, 337-8
women see females
see also stress incontinence; urge UI
Urinary Incontinence Handicap Inventory (UIHI), 381
Urinary Incontinence Score (UIS), 381
Urinary Incontinence Severity Score (UISS), 381
Urinary Incontinence Treatment Network (UITN), 1752, 1754
Urinary Incontinence-4 Questionnaire, 388
Urinary Sensation Scale (USS), 389, 390
urinary sphincter
artificial see artificial sphincter
natural see urethral sphincter
Urinary Symptom Profile (USP), 381
urinary tract, lower/upper see lower urinary tract; upper urinary tract
urinary tract infections (UTIs)
artificial urinary sphincter-related, 1168
bladder pain syndrome and
differential diagnosis, 1479
UTI in aetiology, 1470
children
bladder reconstruction/augmentation and, 757-8
with neurogenic detrusor-sphincter dysfunction, 743-4
recurrent, day and night enuresis and, 728-9
indwelling catheter-related, 818, 1564-6, 1590-6
personal hygiene in prevention of, 1601
intermittent catheter-related, 817, 1577, 1581-2
men, UI risk, 69
multiple sclerosis, 895
in neurogenic detrusor overactivity patients, botulinum toxin A
effects on incidence of, 663-4
older people, 309
spinal cord injury, 898
prevention, 904
treatment, 904
SUI surgery-related, 1236
urine drainage bag-related, 1564-8
urothelial response, 171
women, UI risk, 59
see also antibiotics; bacteriuria; cross-infection
urination see micturition; voiding
urine
analysis see urinalysis
collection
in drainage bags see drainage bags
from indwelling catheters, 1601-2
see also valves
cytology, males, 352
flow see urine flow
leakage see leakage
loss (in enuresis), quantification, 708
production/output
24-hour, measurement, 336
excessive see nocturia; polyuria
nocturnal, children, 716-17
residual volume see residual urine
skin soiling and irritation, 1618-19
storage
in drainage bags
in re-useable, 1602-3
cleansing products, 1622
storage see storage
vaginal entrapment, 733
voided volume see volume
see also glucosuria; haematuria
urinary retention (UR)
bolus injection, 706
bladder pressure and, relationship see pressure-flow studies
measuring rate of see uroflowmetry
normal rate in children, 706
urine
urinary diversion
artificial urinary sphincter complicated by, 1163
assessment see assessment
children see children
classification by symptoms, 336
conservative management see conservative/medical management
definition, 334
devices for see continence devices
drug therapy see drug therapy
epidemiology see epidemiology
episode frequency, assessment, 336
extra-urethral, endoscopy, 609
FI and, association, 1333
guidelines, 1664-5
help-seeking see help-seeking behaviour
historical perspectives, 19-34
imaging see imaging
impact and consequences, 61-2
LUTS with, urodynamic studies in men, 450-1
men see males
neurological causes see neurogenic LUT dysfunction and incontinence
obstetric see childbirth; pregnancy
odour control products, 1626
older people see frail elderly; older people
overactive bladder with (OAB_dry), 72
overactive bladder without (OAB_dry), 72
overflow, urodynamic studies, 456
pathophysiology, 257-78, 299-311, 799
men, 299-308
men, post-prostatectomy, 1128
women, 271-8, 448-9
women, post-fistula repair, 1448
POP comorbid with see pelvic organ prolapse
post-fistula repair, 1448-50
prevention see prevention
reflex see reflex bladder
screening tools, 383-8
severity see severity
surgery see surgery
transient see transient UI
types, 334
  continuous, definition, 334
  mixed see mixed UI
urinalysis, 337-8
women see females
see also stress incontinence; urge UI
Urinary Incontinence Handicap Inventory (UIHI), 381
Urinary Incontinence Score (UIS), 381
Urinary Incontinence Severity Score (UISS), 381
Urinary Incontinence Treatment Network (UITN), 1752, 1754
Urinary Incontinence-4 Questionnaire, 388
Urinary Sensation Scale (USS), 389, 390
urinary sphincter
artificial see artificial sphincter
natural see urethral sphincter
Urinary Symptom Profile (USP), 381
urinary tract, lower/upper see lower urinary tract; upper urinary tract
urinary tract infections (UTIs)
artificial urinary sphincter-related, 1168
blanket therapy
primary/secondary care, 901-2
programme, 901-2
self-help see self-help
urgency see urgency
urinary retention (UR)
bladder pressure and, relationship see pressure-flow studies
measuring rate of see uroflowmetry
normal rate in children, 706
urine
urinary diversion
artificial urinary sphincter complicated by, 1163
assessment see assessment
children see children
classification by symptoms, 336
conservative management see conservative/medical management
definition, 334
devices for see continence devices
drug therapy see drug therapy
epidemiology see epidemiology
episode frequency, assessment, 336
extra-urethral, endoscopy, 609
FI and, association, 1333
guidelines, 1664-5
help-seeking see help-seeking behaviour
historical perspectives, 19-34
imaging see imaging
impact and consequences, 61-2
LUTS with, urodynamic studies in men, 450-1
men see males
neurological causes see neurogenic LUT dysfunction and incontinence
obstetric see childbirth; pregnancy
odour control products, 1626
older people see frail elderly; older people
overactive bladder with (OAB_dry), 72
overactive bladder without (OAB_dry), 72
overflow, urodynamic studies, 456
pathophysiology, 257-78, 299-311, 799
men, 299-308
men, post-prostatectomy, 1128
women, 271-8, 448-9
women, post-fistula repair, 1448
POP comorbid with see pelvic organ prolapse
post-fistula repair, 1448-50
prevention see prevention
reflex see reflex bladder
screening tools, 383-8
severity see severity
surgery see surgery
transient see transient UI
types, 334
  continuous, definition, 334
  mixed see mixed UI
urinalysis, 337-8
women see females
see also stress incontinence; urge UI
Urinary Incontinence Handicap Inventory (UIHI), 381
Urinary Incontinence Score (UIS), 381
Urinary Incontinence Severity Score (UISS), 381
Urinary Incontinence Treatment Network (UITN), 1752, 1754
Urinary Incontinence-4 Questionnaire, 388
Urinary Sensation Scale (USS), 389, 390
urinary sphincter
artificial see artificial sphincter
natural see urethral sphincter
Urinary Symptom Profile (USP), 381
urinary tract, lower/upper see lower urinary tract; upper urinary tract
urinary tract infections (UTIs)
artificial urinary sphincter-related, 1168
bladder pain syndrome and
definition, 417-18
EMG with, 440, 532
females see females
frail elderly, 468-73, 977
imaging combined with see videourodynamics
males, 450-5
preoperative, 1124-6
methods used, see also specific methods
neuropathic LUT dysfunction, 455-7, 804-6, 1743
multiple sclerosis, 896-7
spina bifida (incl. myelomeningocele), 458-9, 913
spinal cord injury see spinal cord lesions
in outcomes measurement
in LUTS, 1733-4
in UI surgery in women, 1252-3
post-prostatectomy UI, 451-4
preoperative
cost-effectiveness, 1707
males, 1124-6
reproducibility, 423-6
research see also research
role, 418
technological innovations, 419-23
training in, 1661
uroflowmetry, 418-19
children, 708-9
geriatric patients, 469, 472
urogenital diaphragm, female, 271-2
Urogenital Distress Inventory (UDI) and UDI-6, 382, 382-3, 387, 389, 390
urogenital fistula see fistula
urogenital sinus malformation, 745
urography, intravenous, 548
Urolife, 381
Urolume™, 835, 836, 837
uropathogenic Escherichia coli, 117, 171
uroplakin, 170
urotheliohypoplastic hypothesis of spontaneous detrusor activity, 124, 124-5
urothelium (transitional epithelium), 116-20, 170-5
afferent nerves, 177
anatomy, 170
barrier function, 170
in bladder pain syndrome aetiology
cell proliferation, 1470
dysfunction, 1470
cells, role in visceral sensation, 171-5
detrusor interactions with, 120
in disease and infection, 117
heterogeneity, 171
muscarinic receptors, 638
in paediatric surgery, colicoplasty lined with urothelium (=seromuscular patch), 749
secretory properties, 117-19
signalling properties see signalling
urotherapy (bladder rehabilitation), children, 734-6, 769-71
URS (Urgency Rating Scale), 389, 390
USA see United States
USP (Urinary Symptom Profile), 381
USS (Urinary Symptom Scale), 389, 390
uterus
damage in obstructed labour, 1432
interactions with other pelvic organs at effenter neural level, 203-5
prolapse
MRI, 590
surgery, 1280
U-Tex male adjustable tension band, 1576
UTP, 120
UU scale (10-Item Scale to Measure Urinary Urgency), 391
V
VACTERL association, 463
vacuum (ventouse) delivery, trauma due to, 297, 298, 1337
MRI, 587
vagina
age-related changes, 969
damage/injury in obstructed labour, 1431-2
delivery via see childbirth
devices in see intravaginal devices
examination
in bladder pain syndrome, 1474
in UI, 344
fistulas involving, aetiology and epidemiology in developing
world, 1422-9
see also rectourethral fistula; rectovaginal fistula; urethrovaginal fistula
pain in bladder pain syndrome, 1475
POP pathophysiology related to alterations of vaginal tissues, 280-1
sling material extruded into, 1235
urine entrapment (girls), 733
vault prolapse, surgery, 1280
see also pubovaginal sling and entanglements under colposcopic approach
transvaginal approach see transvaginal approach
vaginal biofeedback see biofeedback
vaginal cones, weighted, 1052-3, 1056-8, 1080
combined with other treatments, 1058
pelvic floor muscle training, 1052, 1053, 1058
future research directions, 1081
literature search strategies, 1107
pelvic floor muscle training vs, 1048, 1050, 1051
recommendations for practice, 1080
vaginal prolapse
childbirth and, 272-3
SUI surgery-related, 1236
vaginal tape, tension-free see tension-free vaginal tape
vaginal wall, apical, as key to pelvic organ support, 1278-9
vaginal wall prolapse
anterior (cystocele)
cystourethrography, 556
materials augmenting surgery, 1300-1, 1303-4
physical examination, 345
SUI risk following surgery, 448
surgery, 1280, 1288-90
apical, 1278-86
materials augmenting surgery, 1306
physical examination, 345
surgery (support procedures), 1278-86
posterior (rectocele)
imaging, 567, 589-90, 593
materials augmenting surgery, 1305
physical examination, 345
surgery, 1280, 1290-1
vaginitis, atrophic, 390
validity
pad test, 619
patient-reported outcome questionnaires, 366, 367
trials, bias and blinding effects on, 1722-3
valproate sodium, 1351
Valsalva manoeuvre
bladder expression using, 813-14
leak point pressure in, 274, 422, 432, 433, 434, 443, 444, 446
preoperative, men, 1124-5
in Q-tip test, 343
in ultrasound, 559, 561, 565, 567, 571
valves
catheter, 1601-2, 1606, 1610
vesicovaginal fistulas, 24-7
vesicovaginal entrapment, 733
vesicovaginal fistulas, 24-7
vesicovaginal fistula, 603
Vesicoureteric reflux
Vertebral (spinal) canal stenosis, 801, 908-9
Vertebral column see spine
Vertebral column
Vesical autoplasty, 1446-7
Vesicosphincteric disorders in multiple sclerosis, 894-6
Voiding
Voided volume
Vitamin B12 deficiency, intestinal reservoir-related, 756
Visual Analogue Scale, symptoms in bladder pain syndrome, 1475
Visco-elasticity, LUT, 134
Visceral pelvic fascia
Viscera, pelvic
Videourodynamics (urodynamics + imaging incl. videocystourethrography), 440, 551-2
Vesicovaginal fistulas, 24-7
Vesicovaginal fistula, 603
Washing
Waking
Waking
Water
Water-tight fistula closure, 1440, 1443
Waveform analysis in neurophysiological tests, 527
Wetting
Whole body, 1667
Whole body, reduction, 1667
White matter structural lesions, frail elderly, 972
World Health Organization (WHO) on fistulas
Fistula Surgeons Experts Meeting in Geneva (2004), 1439-40
World Federation of Incontinent Patients, 1683
World Health Organization (WHO) on fistulas
Fistula Surgeons Experts Meeting in Geneva (2004), 1439-40
Worldwide issues, see entries under international
appendix
Worldwide issues
Wound infection in SUI surgery, 1236
xenograft slings, 1216

Y

YIPS (York Incontinence Perceptions Scale), 381
YM178, 658
YM905 see solifenacin
yogurt, 1347
York Incontinence Perceptions Scale (YIPS), 381
York-Mason approach to rectourethral fistula, 1156
Young, Hugh H, 28

Z

ZD0947, 653
zinc cream BP, 1624
zirconium oxide beads, pyrolytic carbon coated (Durasphere), 1404
zoster, 921
Zuidex see hyaluronic acid-dextranomer co-polymer